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General introduction and outline of the thesis 
 
Breast cancer  
Breast cancer is the most common cancer in women1: in the Netherlands, the lifetime risk of being 
diagnosed with invasive breast cancer has increased over the past decades from 10.5% to 13.6%, 
meaning one of seven women will be diagnosed with invasive breast cancer2. At the same time, the 
oncological outcome of breast cancer patients has improved substantially in the last decades, with a 
10-year survival rate of almost 80%, resulting in an increasing number of long-term survivors2,1. 
Herewith, any late side effects of treatment and their possible negative impact on survival or quality 
of life are increasingly important for these patients3,4. Consequently, there is growing attention for 
limiting these side effects as much as possible, whilst maintaining the good oncological outcome.  
Apart from surgery and systemic treatment, radiotherapy plays a major role in the treatment of breast 
cancer. In patients with early breast cancer, breast conserving therapy, i.e. lumpectomy followed by 
breast irradiation, is nowadays considered as standard of care. The twenty-year results of the B-06 
study  showed that in patients with early breast cancer less recurrences occurred after lumpectomy 
followed by breast irradiation compared to lumpectomy alone, with an equal survival as in patients 
who received a mastectomy5. Adjuvant radiotherapy shows a relative reduction in loco-regional 
recurrences of 60-70%6 in patients treated with breast conserving surgery. An additional boost to the 
tumour bed reduces the risk for local failure even further by a factor of 27. 
For a long time, it has been thought that radiotherapy only reduced local recurrences, but since a few 
decades we know that radiotherapy also can improve overall survival8,9. There is a significant relation 
between the risk of a local recurrence and overall survival, indicating that by preventing four local 
recurrences, one breast cancer death could be prevented at 15 years8. A large meta-analysis 
confirmed this one in four rule, but also nuances these numbers. The number of breast cancer deaths 
avoided per recurrence avoided might be more than one in four in pN+ disease and in high risk pN0 
disease, and less than one in four for women with intermediate or low risk disease9.  
 
Radiation induced side effects 
Interaction of ionizing radiation with tissue cells causes damage (sometimes irreversible) to the 
cellular DNA, with cell kill and hereby tissue damage as a result. Although tumour cells are generally 
more sensitive to radiation compared to normal tissue cells10, normal tissue damage does occur. 
Therefore, the main objective of radiotherapy is to administer a lethal dose to the tumour, while 
avoiding surrounding normal tissue damage as much as possible.  
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In breast cancer, radiotherapy is usually administered after surgery. Therefore, in the majority of 
patients, no macroscopic tumour is present anymore in the breast and the radiation treatment is 
aimed at preventing a local recurrence. The whole breast (or partial breast) supplemented or not with 
elective regional nodal areas is included in the Clinical Target Volume (CTV), defined as the area with 
possible microscopic disease.  Late side effects that have been reported with this loco(regional) 
irradiation are impaired shoulder function, lymphedema, fibrosis of the breast leading to pain and 
impaired cosmetic outcome11.  In addition, radiation-induced lung and cardiac injury may occur12,13.   
The risk of lung toxicity is quite low. In the EORTC 22922/10925 trial only 1.3% of patients suffered 
from lung toxicity (fibrosis; dyspnoea; pneumonitis; any lung toxicities) in case of breast irradiation 
versus 4.3% in case of elective irradiation of the internal mammary and medial supraclavicular nodes 
as well at three years follow up14. Radiation dose to the heart increases the subsequent risk of 
coronary heart disease and cardiac mortality: when comparing patients with radiotherapy and without 
radiotherapy for breast cancer, the relative risks are 1.30 for coronary heart disease and 1.38 for 
cardiac mortality15. In absolute numbers, radiotherapy for breast cancer is associated with an absolute 
risk increase of 76.4 cases of coronary heart disease and 125.5 cases of cardiac death per 100 000 
person-years15.  
 
Although many side effects can occur, in this thesis we mainly focus on the analysis of cosmetic 
outcome in the Young Boost Trial (YBT), a large international Randomized Controlled Trial in which the 
effect of a higher boost dose on local recurrence and cosmetic outcome was investigated. However, 
we also involve heart damage into the thesis, as heart damage is obviously a very important and 
potential lethal late toxicity. In the paragraphs below we describe the background of the subjects of 
this thesis.  
 
Cosmetic outcome and fibrosis 
The EORTC ‘‘boost versus no boost” trial showed that by adding a boost to the tumour bed, the risk 
of local failure can be reduced further compared to irradiation of the whole breast alone16–18. The 
boost versus no boost trial7 also showed that the younger patients still remained at a risk of a local 
failure of 13.5% percent at ten years, which was deemed unacceptable.  
Based upon these results, the YBT was designed in 2003, in which patients of 50 years and younger 
with early breast cancer were randomized between a standard 16 Gy boost or a high 26 Gy boost or a 
scheme with a biological equivalent dose following 50 Gy whole breast irradiation.  The YBT is a large 
international randomized trial in which 2423 patients were included from The Netherlands, France 
and Germany.   
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The first aim of the YBT was to investigate the effect of a higher boost on the local recurrence rate. 
Since the boost versus no boost trial had also shown that the boost resulted in a worse cosmetic 
outcome19, the second aim was to investigate whether or not there is a significant difference in 
cosmetic outcome and fibrosis between the high boost group and the low boost group. 
In order to deliver a proper radiation treatment with the least possible negative side effects, it is 
important to have knowledge of the risk factors for fibrosis and a deteriorated cosmetic outcome. 
Also, we need to know which features are related to the patients’ opinion concerning cosmetic 
outcome.   
Defining cosmetic outcome is often considered as controversial, because of its subjective nature. 
Therefore, besides subjective scores, several automatic methods to score cosmetic outcome are 
available, assuming that an automatic score is more objective and reproducible. An example of an 
objective method is BCCT.core, which is a software program which analyses digital photographs in 
anterior-posterior view, resulting in an objective score for the overall cosmetic outcome: excellent, 
good, fair or poor20. This score is based on symmetry (7 features), skin colour and scar visibility. In this 
thesis, we used the BCCT.core objective score to analyse risk factors for worse cosmetic outcome. 
 
Prevention of cardiac toxicity 
Breast or thoracic wall irradiation is generally largely given using tangential fields. The heart can be 
partially located within the radiation field in case of left-sided breast cancer or in case of irradiation of 
the inframammary lymph nodes, both left- as right sided.  Darby et al13 published in 2013 a very 
important paper which described the effect of radiation to the heart in patients for breast cancer. 
With every Gray to the heart (mean heart dose), rates of major coronary events increase by 7.4%, with 
no apparent threshold. The overall rate ratio for a major coronary event among women with a history 
of ischemic heart disease as compared with women with no such history was 6.67. A history of other 
circulatory diseases, diabetes, chronic obstructive pulmonary disease, smoking, a high body-mass 
index or a history of regular analgesic use were defined as factors associated with an elevated risk of 
coronary events. The rate ratio for the presence of one or more of these factors but absence of 
ischemic heart disease was 1.96 overall. This increase started already within the first 5 years after 
radiotherapy and continued into the third decade after radiotherapy. Therefore, reduction of 
irradiated volume and dose to the heart is expected to reduce late heart toxicity and as a result 
prevent morbidity.  
Proton therapy may be able to reduce heart injury. Since proton therapy has recently become 
available in our country, there was discussion about which patients should be eligible for this new 
technique. In the Netherlands, proton therapy is only being reimbursed, if there is a clinically relevant 
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difference in the probability to develop a certain complication between proton and photon therapy. 
A national indication protocol must be available, containing validated prognostic models to estimate 
the complication probability. Cardiac injury is the only endpoint included in the national indication 
protocol for proton therapy in breast cancer.  The risk on acute coronary events is estimated based on 
the model of Darby et al9 described. Consequently, this model is now also being used in optimizing 
photon treatment plans, i.e. by applying strategies that reduce the mean heart dose. 
Multiple respiratory techniques have been described to spare both heart and lung. All techniques are 
based on the principle that during deep inspiration the heart moves out of the radiation field. This can 
be achieved using advanced methods as an Active Breathing Control (ABC) device21 or gating22,23, but 
also using more simple voluntary breath hold techniques22,24,25. Although the simple technique is 
obviously cost attractive, the reproducibility of this voluntary breath hold technique has however been 
questioned26.  In this thesis we describe the introduction of voluntary moderately deep inspiration 
breath hold (vmDIBH) in our institute. 
 
Long term follow up 
In 2007, the Dutch Health Council (DHC) advised to limit follow-up only to those situations where 
follow-up has been shown to be beneficial for the individual patient.  
Therefore, in The Netherlands, follow-up after 5 years of treatment is largely performed by the 
General Practitioner instead of in the hospital. Consequently, it is extremely difficult for hospitals to 
obtain long-term outcome data of the breast cancer patients treated in their hospital. Since we 
consider structural outcome registration an extremely important prerequisite for improving quality of 
care, we started an outpatient clinic for late outcome of breast cancer patients to explore whether 
registration of late outcome assessed using validated questionnaires (patient reported outcome 
measures (PROMs)) is at least as good as an assessment by the caregiver during a live visit at the 
outpatient clinic.   
 
Outline of this thesis 
In the last decades, the treatment of breast cancer patients has improved substantially and in patients 
with early breast cancer breast conserving therapy is considered as standard of care5,18.  In addition, 
the incidence of breast cancer has risen and the oncological outcome has improved1,2, leading to a 
growing number of breast cancer survivors. Especially in the patient population with a good 
oncological prognosis, preventing late side effects becomes increasingly important.   
The central theme of this thesis was to get insight in several aspects of some late side effects: 
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- To predict cosmetic outcome, not only to have clues how to improve cosmetic outcome, but 
also to use in shared decision making when choosing on radiation treatment. For this purpose, 
we used the data of the Young Boost Trial. In this trial the effect of a higher boost dose on 
local recurrence and cosmetic outcome was investigated in patients ≤ 50 years of age. We 
analysed the cosmetic outcome of the Young Boost Trial.  
- To prevent late side-effects, i.e. cardiac injury, by investigating whether our technique of 
Voluntary moderately Deep Inspiration Breath Hold (vmDIBH) is actually reproducible. 
- To record all late-side effects in a structured way: 
o to identify patients needing additional care 
o to enable development of prognostic models 
o to be able to compare outcome data with other radiation therapy centres or with 
historic controls.  
Consequently, the three main aims of this thesis are:  
1. To determine which factors are important for:  
a. patient reported cosmetic outcome 
b. fibrosis (scored by physician) 
c. cosmetic outcome (based on the objective BCCT.core) 
To determine these factors, we analysed which risk factors are associated with a worse cosmetic 
outcome in the YBT trial, based on the objective BCCT.core score. Further, we report on the 
amount of moderate/severe fibrosis and define the risk factors for moderate/severe fibrosis in 
the boost area (Chapters 2 & 3). 
 
2. To investigate/develop an easy but reproducible and affordable breath hold manoeuvre to reduce 
the dose to the heart (Voluntary moderately Deep Inspiration Breath Hold, vmDIBH). 
Chapter 4 reports on the careful step-by-step introduction of voluntary moderately deep 
inspiration breath hold (vmDIBH) in our institute. To investigate the reproducibility of vmDIBH, we 
compared set-up data of patients treated in vmDIBH and with free breathing patients.  
 
3. To investigate whether patient reported outcome measures (PROMS) are sufficiently reliable to 
record late outcome (Chapter 5). 
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To be able to investigate this, we developed an outpatient clinic for late outcome (OCLO) and 
compared PROMS to the results found at the live visit to the outpatient clinic.  
 
Finally, the findings of these thesis are discussed in chapter 6. A summary and Dutch translation of the 
summary is provided in chapter 7.  
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Abstract 
 
Purpose: To investigate which factors are related to patient reported cosmetic outcome (PRCO) after 
breast conserving therapy. 
 
Methods: From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomised in the Young 
Boost Trial between a 16 and a 26 Gy boost to the tumour bed. Cosmesis was scored subjectively by 
the patient and physician, and objectively using BCCT.core, at baseline, one and four years after 
treatment. Presence of fibrosis, QoL and rib pain at four years were also scored. Data were complete 
for 864 patients. The relation between the separate components was investigated using a 
proportional odds model. 
 
Results: Of the 7 BCCT.core parameters, the distance from nipple to inframammary fold and the length 
of the breast contour were significantly related to the overall PRCO at four years. Patients with more 
fibrosis and poorer QoL scored their cosmesis worse, while rib pain was not related. The agreement 
between the different scores was low (kappa 0.26–0.42). 
 
Conclusion: The distance from nipple to inframammary fold, the length of the breast contour and the 
severity of fibrosis were the main factors related to patient-reported cosmetic outcome. Patients with 
better QoL scored their cosmesis better. 
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Introduction 
The EORTC boost-no boost trial showed that adding a 16 Gy boost to the primary tumour bed after 50 
Gy whole breast irradiation, reduces the local recurrence rate (LRR) with 35%1. Nevertheless, even 
after a boost, the LRR in young patients (≤50 years of age) remained higher than 1% per year. 
Therefore, in 2004, the Young Boost trial (YBT) was launched (NCT00212121), with the primary aim to 
investigate whether a higher boost dose of 26 Gy would further reduce the LRR in young patients. 
Since the boost-no boost trial showed that the boost led to a worse cosmetic outcome2, cosmetic 
outcome was an important secondary endpoint in the YBT. 
Scoring cosmesis is difficult and often considered as controversial, because of its subjective nature. 
For example: Mukesh et al. found that physicians judged cosmetic outcome to be superior after 
Intensity Modulated Radiotherapy (IMRT) compared to 2D radiotherapy, whereas the patient 
reported cosmetic outcome (PRCO) showed no benefit of IMRT3,4. A recent analysis of the START trials 
showed that despite a low agreement between different scoring methods of cosmetic outcome, each 
scoring method could sufficiently discriminate different fractionation schedules5. In most studies 
different scoring methods are reported, including patient questionnaires, scoring by professionals (or 
a panel) and/or a photographic assessment using objective and reproducible software programs, such 
as BCCT.core6 or BAT7. 
Although the objective methods seem to be the most attractive due to their good reproducibility, they 
are mainly based on measures to quantify asymmetry, assuming that symmetry is the most important 
determinant for PRCO. However, if that were true, a much better correlation between PRCO and 
objective measures would be expected than described in literature. We hypothesised that specific 
aspects of symmetry (e.g. nipple position) are more important for patients than other aspects (e.g. 
breast size), and that other factors such as pain or palpable firmness of the breast also influence PRCO. 
The aim of the current paper was therefore to prospectively investigate which objective cosmetic 
factors are associated with PRCO in the YBT. We also analysed the relation between fibrosis, pain and 
quality of life (QoL) with PRCO. 
 
Patients and methods 
Patient population and treatment 
Patients younger than 51 years with non-metastatic, histologically proven invasive breast cancer, pT1-
2pN0-2a8, with an Eastern Cooperative Oncology Group (ECOG) performance scale9 ≤2, were eligible 
for the trial. Tumours were completely removed by wide local excision, although focally involved 
margins were allowed, defined as: ‘‘tumour (ductal carcinoma in situ or invasive carcinoma) on ink in 
an area of less than 4 mm”. Sentinel lymph node biopsy and/ or axillary lymph node dissection had to 
22 
 
be performed. No neo-adjuvant systemic treatment was allowed. No previous history of malignant 
disease, except adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin 
was allowed. 
Patients were randomised to a standard 16 Gy or a high 26 Gy boost to the tumour bed after 50 Gy 
whole breast irradiation. Other fractionation schemes, including simultaneous integrated boost 
techniques were allowed as well, as long as the biologically equivalent dose, calculated with an α/β of 
10 for tumour, was similar. Stratification factors were age (<>40 yr), pathological tumour size (<>3 
cm), oestrogen receptor status, nodal status, interstitial/external boost and institute. Patients were 
stratified at the time of randomisation using a ‘‘randomisation by minimisation” technique. 
The study was centrally approved by the medical ethical committee of the Netherlands Cancer 
Institute and by the local medical ethics committees. All patients gave their written informed consent 
to participate. The study was registered at https://clinicaltrials.gov/show/NCT00212121. 
 
Cosmetic outcome 
Cosmesis was scored prior to radiation therapy, at one year and four years of follow-up. 
 
BCCT.core software 6,10 
Digital photographs in anterior-posterior view were analysed using the BCCT.core software program, 
resulting in an objective score for the overall cosmetic outcome: excellent, good, fair or poor. This 
score is based on symmetry, skin colour and scar visibility (Fig. 1). The seven features of symmetry in 
the BCCT.core program are: 
▪ breast retraction assessment (BRA) 
▪ level of lower breast contour (LBC) 
▪ upward nipple retraction (UNR) 
▪ breast compliance evaluation (BCE; distance from nipple to inframammary fold) 
▪ breast contour difference (BCD) 
▪ breast area difference (BAD) 
▪ breast overlap difference (BOD) 
 
For all symmetry features a relative value was calculated by the program resulting in a pBRA, pLBC 
etcetera. An example of these relative values is shown in Fig. 1. 
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Fig. 1. BCCT.core software program. In (A) a screenshot of the program is shown, in (B–D) examples 
of some BCCT.core parameters, including formulas for the relative value. 
(A) Screenshot of the BCCT.core software program. (B) Breast Retraction Assessment (BRA).  
(C) Lower Breast Contour (LBC). (D) Breast Overlap Difference (BOD). 
 
 
Physician’s score 
Physicians scored using the Harris scale on overall cosmetic outcome: excellent, good, fair or poor11. 
 
Patient’s questionnaire 
The PRCO was determined by asking patients to complete the questionnaire developed by Sneeuw et 
al12. In this validated questionnaire overall cosmetic outcome was rated on a five-point scale: very 
satisfied, satisfied, not dissatisfied, dissatisfied and very dissatisfied. The patients were also asked to 
rate the difference between the treated breast and the untreated breast in terms of scar visibility, 
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difference in size, shape, colour, nipple position, and firmness on a four-point scale: no difference, 
small difference, quite a lot difference, or a large difference. 
 
Other variables 
At the same time points fibrosis (whole breast) was scored by the physician on a four-point scale. The 
presence of rib pain was scored separately (yes/no). 
At four years, quality of life (QoL) was scored using the EORTC QLQ C-30 questionnaire13. The global 
QoL was measured on a scale from 1 to 7. Emotional functioning was measured on a multi-item scale 
ranging from 0 to 100. The parameter value was calculated for a difference of 10 points. Depression 
was measured at a scale from 1 to 4. A higher score on the functional scale and global QoL implies 
better score, while a higher score on the depression scale implies more symptoms. 
 
Analysis 
First, we analysed the correlation of overall cosmetic outcome between the three scoring methods, 
and between fibrosis scored by the physician and firmness of the breast scored by the patient. 
Secondly, we analysed the seven features of BCCT.core in a proportional odds model, to investigate 
which parameters were related to the PRCO at four years. Also, we analysed whether fibrosis, 
presence of rib pain or QoL was related to the PRCO. 
To evaluate the correlation between the different factors and overall cosmetic outcome, we defined 
two categories: satisfactory overall cosmetic outcome and unsatisfactory overall cosmetic outcome. 
Excellent and good as well as very satisfied and satisfied were grouped as ‘satisfactory’; fair and poor, 
not dissatisfied, dissatisfied, and very dissatisfied were grouped as ‘unsatisfactory’. 
 
Statistics 
Agreement between the three different scoring systems was calculated by Cohen’s kappa statistics. 
The kappa coefficient (k) is a common measure for agreement14. The overall cosmetic outcome was 
evaluated on a five-point scale by the patient’s questionnaire but on a four-point scale by the 
BCCT.core software and physician. Therefore, the agreement of the overall cosmetic outcome was 
assessed using the grouped dichotomised outcome variable as described above. For the agreement 
on individual (separate) cosmetic outcome parameters, all three used a four-point scale and therefore 
a weighted kappa (wk) was used, where the weights were chosen quadratic. A value of 0–0.2 for k 
indicates a slight agreement, 0.2–0.4 indicates a fair agreement, 0.4–0.6 indicates a moderate 
agreement, 0.6–0.8 indicates a substantial agreement and a value of 0.8–1.0 indicates an almost 
perfect agreement. 
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Associations between PRCO and the seven BCCT.core parameters were assessed with proportional 
odds models, taking into account the ordinal nature of the outcome. For each type a higher score 
means a worse outcome. An important assumption of this cumulative link model is that the 
association between each pair of outcome groups is the same, so that for example the comparison 
between a score of 1 versus a score of 2, 3 or 4, and the comparison of 1 or 2 versus 3 or 4 can be 
modelled by the same parameter. This is called the proportional odds assumption. To assess whether 
pain, fibrosis or QoL parameters were associated with worse PRCO, these were analysed in models 
where the BCCT.core outcome was entered as a covariate. The adjustment for BCCT.core outcome 
gives the parameters for fibrosis, rib pain, or QoL the interpretation of what the difference would be 
between two patients with the same BCCT.core outcome who differ only in their fibrosis, rib pain or 
QoL. The QoL parameters were entered as a continuous variable in the model. 
 
 
 
 
Fig. 2. Flow diagram of available and evaluable digital photographs, available patients’ questionnaires 
and completed Case Report Form (CRF) of all institutes per July 2014. 
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Results 
Between 2004 and 2011, 2421 breast cancer patients were included in 18 institutes from The 
Netherlands, 13 institutes from France and 1 institute from Germany. 1211 patients were randomised 
to receive a standard 16 Gy boost and 1210 patients to a high 26 Gy boost. 
Median age was 45 years (range 19–51), 19% was younger than 40 years old. 72% of patients had a 
T1 tumour and 28% of patients had a T2 tumour. 61% of patients received adjuvant chemotherapy 
and 39% did not receive adjuvant chemotherapy. Median follow-up at the time of this analysis was 51 
months. 
At four years we had evaluable digital photographs of 805 patients, of whom 684 also had an evaluable 
photograph at baseline. 1204 patients filled in the questionnaire at baseline, of whom 697 filled one 
in at four years too. The cosmetic result was scored by the physician for 1914 patients at baseline, and 
for 864 at both baseline and 4 years (Fig. 2). 
 
Overall cosmetic outcome for the different scoring systems, and correlation between scoring systems 
At four years, the BCCT.core program yielded a ‘satisfactory’ (i.e. excellent or good) overall cosmetic 
outcome in 61% of patients. The physicians and patients scored the overall cosmetic outcome as 
‘satisfactory’ in 56% and 57% of patients, respectively. The agreement between the physician and the 
patient scores was moderate (k = 0.42), between the patient and BCCT.core fair, and between the 
physician and BCCT.core scores the agreement was fair, with k values of 0.26 and 0.39, respectively. 
The agreement between firmness scored by the patient and the grade of fibrosis scored by the 
physician was fair (wk = 0.36, 95% CI 0.29–0.42) (Table 1). 
  
 Patients’ score of firmness 
no 
difference 
little 
difference  
quite a lot 
difference 
large 
difference 
total number 
of patients 
Physician: no fibrosis 70 101 28 11 210 
Physician: mild fibrosis 70 157 63 19 309 
Physician: moderate fibrosis 19 96 77 25 217 
Physician: severe fibrosis 3 19 20 27 69 
total number of patients 162 373 188 82 805 
 
Table 1. Agreement between fibrosis scored by the physician and the firmness scored by the patient 
at four years, wk = 0.36 (95% CI 0.29–0.42). Firmness was scored in the questionnaire of Sneeuw by 
comparing the treated breast with the contralateral breast. 
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Objective factors associated with patient reported cosmetic outcome 
Of the seven BCCT.core parameters, pBCE (distance from nipple to inframammary fold) and pBCD 
(length of breast contour) were significantly associated with a worse PRCO at four years (Table 2). 
Patients with fibrosis had worse PRCO than patients without fibrosis, even when the objective score 
based on BCCT.core was similar (i.e. after adjustment for it). The same was true for difference in 
firmness scored by the patient. However, the presence of rib pain had no influence (Table 3). 
Of the EORTC QLQ C-30 questionnaire, we analysed whether emotional functioning, feelings of 
depression and/or global quality of life influenced PRCO. For the same BCCT.core score, patients with 
a higher emotional functioning or better global QoL had a better PRCO, whereas patients with feelings 
of depression had a worse PRCO (Table 4). 
  
 
 
 
 
Odds radio 
95% confidence 
interval 
p-value 
pBRA 1.319 0.904–1.921 0.150 
pLBC 1.142 0.792–1.648 0.477 
pUNR 1.056 0.723–1.544 0.779 
pBCE 1.177 1.008–1.375 0.040 
pBCD 1.718 1.024–2.894 0.041 
pBAD 0.856 0.540–1.352 0.505 
pBOD 1.038 0.764–1.409 0.812 
 
Table 2. Proportional odds model for Patient Reported Cosmetic Outcome (PRCO) based on the seven 
BCCT.core parameters. The symmetry features are dimensionless. Significant p-values are indicated in 
bold. An odds ratio >1 means a worse PRCO. The 7 features of symmetry in the BCCT.core program 
are: breast retraction assessment (BRA); level of lower breast contour (LBC); upward nipple retraction 
(UNR); breast compliance evaluation (BCE; distance from nipple to inframammary fold); breast 
contour difference (BCD); breast area difference (BAD); breast overlap difference (BOD). The pre-suffic 
refers to the relative value of this parameter calculated by the program. 
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 Odds ratio 95% Confidence interval  p Value 
   A    
BCCT.core score: 2 1.668 1.058–2.641 0.028 
BCCT.core score: 3 3.856 2.348–6.372 <0.001 
BCCT.core score: 4 9.479 4.835–18.729 <0.001 
Fibrosis score: minor 1.183 0.797–1.760 0.404 
Fibrosis score: moderate 2.022 1.314–3.121 0.001 
Fibrosis score: severe 2.519 1.372–4.635 0.003 
B    
BCCT.core score: 2 1.683 1.086–2.618 0.020 
BCCT.core score: 3 2.735 1.695–4.431 <0.001 
BCCT.core score: 4 4.6163 2.427–8.812 <0.001 
Difference firmness: small 1.700 1.152–2.516 0.008 
Difference firmness: quite a lot 5.207 3.291–8.288 <0.001 
Difference firmness: large 16.262 8.839–30.242 <0.001 
C    
BCCT.core score: 2 1.772 1.140–2.765 0.011 
BCCT.core score: 3 4.696 2.926–7.585 <0.001 
BCCT.core score: 4 11.763 6.265–22.269 <0.001 
Rib pain score: some 1.123 0.746–1.690 0.577 
Rib pain score: moderate 0.945 0.235–2.690 0.915 
Rib pain score: severe 1.988 0.531–7.567 0.306 
 
Table 3. Proportional odds model for patients’ satisfaction with A: fibrosis scored by physician  
and BCCT.core score as covariate, B: difference in firmness scored by the patient and BCCT.core score 
as covariate and in C: rib pain and BCCT.core score as covariate. Odds ratios higher than 1 indicate 
that a higher value of the parameter was associated with a worse patient satisfaction. Significant p-
values are indicated in bold. 
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 Odds ratio 95% Confidence interval  p Value 
   A    
BCCT.core score: 2 1.614 0.996–2.623 0.053 
BCCT.core score: 3 4.885 2.902–8.286 <0.001 
BCCT.core score: 4 8.507 4.283–17.052 <0.001 
Emotional functioning 0.881 0.813-0.955 0.002 
B    
BCCT.core score: 2 1.648 1.018–2.679 0.043 
BCCT.core score: 3 4.825 2.867–8.179 <0.001 
BCCT.core score: 4 9.250 4.670–18.498 <0.001 
Feelings of depression 1.366 1.081–1.724 0.009 
C    
BCCT.core score: 2 1.621 0.999–2.638 0.051 
BCCT.core score: 3 4.709 2.796–7.988 <0.001 
BCCT.core score: 4 8.618 4.318–17.347 <0.001 
Global quality of life 0.790 0.685–0.909 0.001 
 
Table 4.  
Proportional odds model for Patient Reported Cosmetic Outcome (PRCO) and quality of life with 
BCCT.core as covariate. A: emotional functioning with BCCT.core as covariate, B: feelings of depressing 
and C: global quality of life with BCCT.core as covariate. Significant p-values are indicated in bold. For 
BCCT core parameters, an odds ratio >1 means a worse PRCO. For Emotional functioning, Global 
quality of life, and depression an odds ratio >1 means worse PRCO in case of worse Emotional 
functioning, QoL, or more feelings of depression. 
 
 
Discussion 
The most important parameters related to PRCO after BCT in the YBT were the distance from nipple 
to inframammary fold and the length of breast contour. Also, the severity of fibrosis (physician) and 
the difference in firmness (patient) was related to the PRCO, independent of the BCCT.core score, 
suggesting that indeed a palpable firmness subjectively influences the patient’s opinion on cosmesis. 
Rib pain was not related to the PRCO. 
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Comparison with the literature 
Christie et al15 found, in a population of 47 patients, that a greater degree of upward retraction of the 
nipple was the most powerful determinant of PRCO. This may be inversely related to the pBCE, i.e. the 
distance from nipple to inframammary fold, which we found in our study. 
Patient’s mental state might influence PRCO as well. Brunault et al. showed that depression is 
associated with patient-perceived cosmetic changes16. Patients with a probable depression perceived 
the treated breast to be larger, more deformed and having worse skin pigmentation than non-
depressed patients16. 
The current study finds similar results: patients with feelings of depression had worse PRCO than 
patients with better emotional functioning or better global QoL. However, it is difficult to distinguish 
between cause and effect in this matter. It might also be true that a better cosmetic result yields a 
better QoL. 
Recently the cosmetic results of the START trials were published. In this study, PRCO of 1870 patients 
was unaffected by anxiety and depression5. A possible explanation for the different findings could be 
the difference in age, since in the Cambridge IMRT trial young age was also found to influence the 
symptoms of skin appearance and breast hardness4. 
 
Correlation between BCCT.core and physician’s opinion and/or patient’s opinion 
BCCT.core versus physician 
Cardoso et al6 evaluated the validity of the BCCT.core software by a panel of experts. Overall inter-
observer agreement for the subjective score was fair to moderate (k = 0.40, wk = 0.57), whereas the 
concordance level for the objective BCCT.core measurement was much higher (k = 0.86, wk = 0.90). 
The agreement between the subjective measurement and the BCCT.core was only fair (k = 0.34, wk = 
0.53), but increased to moderate if scale 2 and 3 of the Harris scale were merged to a 3-point scale  
(k = 0.57, wk = 0.72). We found on a two-point scale, i.e. satisfactory or non-satisfactory overall 
cosmetic outcome, a somewhat lower correlation between BCCT.core score and physician scores: 
0.39. A possible explanation is that in the YBT the cosmetic evaluation was scored only by the treating 
physician instead of by a panel that reached consensus. 
 
BCCT.core versus patient 
The correlation between objective measures and PRCO shows reported k values varying from 0.04 to 
0.3417,18, which corresponds to the value of 0.26 found in our study. The different kappa values in the 
different studies can probably be ascribed to different methods to measure PRCOs. Yu et al. used a 
conversation with researchers not involved in treatment of patients18. Heil et al. used a validated 
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patient questionnaire BCTOS (Breast Cancer Treatment Outcome Scale)17, but another one than ours 
12. In both questionnaires (BCTOS and ours12), patients were asked to rate seven items according to 
symmetry. In the BCTOS the rounded mean of these seven items was used as an overall score, while 
we compared only the last question in our questionnaire12 with the BCCT.core score, since that 
question dealt with the overall PRCO. 
The fact that the PRCO correlated less with the overall BCCT.core score than the physician’s opinion, 
confirms our hypothesis that specific symmetry parameters were more important than others. 
Furthermore, we found that also other factors such as fibrosis, not directly measured by BCCT.core, 
influenced PRCO. 
 
Correlation between physicians’ and patients’ opinion 
Several studies comparing patient with physician’s reported overall cosmetic outcome showed various 
results. In some studies, similar to our study, patients scored their cosmesis and/or normal tissue 
effects worse than the clinician4,19 or photographic assessment19, while other studies, showed 
opposite results20,21. 
The START trial5 also reported on agreement between PRCOs and clinical or photographic assessments 
of breast specific normal tissue effects. They found wk coefficients of 0.05–0.21. These lower values 
might be explained by the difference in questions. For example, in the START trial telangiectasia 
(clinicians) was correlated with skin changes (patient) which could mean more than only telangiectasia 
(wk = 0.08 at 5 years). Also, in some questions the patient was asked to indicate whether their scoring 
was influenced by radiotherapy, which is difficult if not impossible to judge by the patient. Another 
difference with our study was that the photographic assessment was performed by a panel, whilst we 
used an objective software program to analyse the photographs. 
 
Overall cosmetic scores 
The overall cosmetic outcome in the YBT was worse than published in most other studies. Only Haloua 
et al. found similar results as we did 20. However, no data on radiation dose were given in this paper. 
In the boost versus no boost trial 86% of the patients had excellent or good score in the no boost 
group compared to 71% in the boost group at 3 years2, whereas in the YBT these scores were only 
found in 56–61%, dependent on the scoring method. 
Better cosmetic outcome results are also reported by Kelemen et al22 and Hau et al21. Hau et al. found 
excellent/good cosmesis, scored by physician or patient in 95% and 93% in the boost- and no-boost-
arm respectively) versus 81% (boost) and 68% (no boost) according to the BCCT.core software21. In 
this trial the whole breast dose was lower in the boost-arm than in the no-boost-arm. 
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A possible explanation for the worse cosmetic outcome results in the YBT is that half of the patient 
population received a high (26 Gy) boost. Detailed analysis of the effect of these treatment related 
factors on overall cosmetic outcome will be performed and presented in a separate paper. 
 
Strengths and limitations 
This study is the largest study reported up till now addressing the question which objective parameters 
are related to PRCO. In a large subset of patients, three kinds of cosmetic analyses were performed. A 
limitation of this study is that it comprises only a subset of the total number of patients included in 
the YBT. This may have several causes, like the relatively short median follow up of 51 months and the 
usual delay for sending in CRFs. For some patients not all digital photographs were available, or not 
usable due to quality or technical issues. Since we only analysed quantitative variables, we expect that 
the missing data did not significantly affect our overall results. 
Another important aspect to take into account is that all patients were 50 years or younger. It is thus 
not clear whether the same correlation exists in elderly patients. 
  
Conclusion 
Patient reported cosmetic outcome is mostly related to the distance from the nipple to the 
inframammary fold, the length of the breast contour, and by the severity of fibrosis. Patients with 
higher emotional functioning or better QoL scored their cosmesis better. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
Conflict of interest 
None declared. 
 
 
Acknowledgments 
The data management of the YBT was supported by a grant of the Dutch Cancer Society (CKTO 2003-
13). The analysis of cosmetic outcome in this paper was supported by a Pink Ribbon grant (2011. 
WO04.C94). The French part of the trial was funded by the French Ministry of Health PHRC2009 and 
PHRC2012 grants. 
Further, the authors thank J. Cardoso and M. Cardoso for the use of the BCCT.core software program, 
B. Hanbeukers for analysing the majority of digital photographs using the BCCT.core. software, and L. 
Pronk en R. Muusers for data retrieval. 
 
Also, we acknowledge and thank Jerôme Lemonnier, project leader in France, for coordinating the 
Young Boost Trial in France and the following for their active participation: M. van Hezewijk, Leiden 
(NL); M.J.C. van der Sangen Eindhoven (NL); M.C. Stenfert Kroese, Deventer (NL); J.J.Jobsen, Enschede 
(NL); J.M. Immink, Delft (NL); M.E. Mast, Den Haag (NL); F.M. Gescher, Den Haag (NL); N. Bijker, 
Amsterdam (NL); J.W.M. Mens, Rotterdam (NL); W.G.J.M. Smit, Leeuwarden (NL); D.H.F. Rietveld, 
Amsterdam (NL); I. Lecouillard, Rennes (Fr); C Breton-Callu, Bordeaux (Fr); H. Marsiglia, Villejuif (Fr); J. 
Thariat, Nice (Fr); A. Benyoucef, Rouen (Fr); A. Labib, Saint Cloud (Fr); M. Aumont, Saint Herblain (Fr); 
P. Bon-temps, Besancon (Fr); C. Le Foll, Lagny (Fr); Y. Belkacemi, Créteil (Fr); O. Chapet, Lyon (Fr); V. 
Strnad, Erlangen (De). 
 
 
 
 
 
34 
 
References 
 
1. Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for 
patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a 
randomised phase 3 trial. Lancet Oncol 2015;16:47–56.. 
 
2. Vrieling C, Collette L, Fourquet A, et al. The influence of the boost in breast-conserving therapy on 
cosmetic outcome in the EORTC ‘‘Boost versus no Boost” Trial. Int J Radiat Oncol 1999;45:677–85. 
 
3. Mukesh MB, Barnett GC, Wilkinson JS, et al. Randomized controlled trial of intensity-modulated 
radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol 
2013;31:4488–95.  
 
4. Mukesh MB, Qian W, Wilkinson JS, et al. Patient reported outcome measures (PROMs) following 
forward planned field-in field IMRT: results from the Cambridge Breast IMRT trial. Radiother Oncol 
2014;111:270–5. 
 
5. Haviland JS, Hopwood P, Mills J, Sydenham M, Bliss JM, Yarnold JR. Do Patient-reported Outcome 
Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast 
Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in 
Early Breast Cancer. Clin Oncol 2016:1–9.  
 
6. Cardoso MJ, Cardoso J, Amaral N. Turning subjective into objective: the BCCT.core software for 
evaluation of cosmetic results in breast cancer conservative treatment. Breast 2007;16:456–61.  
 
7. Fitzal F, Krois W, Trischler H, et al. The use of a breast symmetry index for objective evaluation of 
breast cosmesis. Breast 2007;16:429–35.  
 
8. Sobin LH, Gospodarowicz MK WC. TNM Classification of Malignant Tumors; 2002.  
 
9. Young J, Badgery-Parker T, Dobbins T, et al. Comparison of ECOG/WHO performance status and 
ASA score as a measure of functional status. J Pain SymptomManage 2015;49:258–64. 
 
10. Cardoso JS, Cardoso MJ. Towards an intelligent medical system for the aesthetic evaluation of 
breast cancer conservative treatment. Artif Intell Med 2007;40:115–26.  
 
11. Harris JR, Levene MB, Svensson G, Hellman S. Analysis of cosmetic results following primary 
radiation therapy for stages I and II carcinoma of the breast. Int J Radiat Oncol 1979;5:257–61.  
 
12. Sneeuw KC, Aaronson NK, Yarnold JR. Cosmetic and functional outcomes of breast conserving 
treatment for early stage breast cancer. 1. Comparison of patients’ ratings, observers’ ratings, 
and objective assessments. Radiother Oncol 1992;25:153–9.. 
 
13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and 
Treatment for Use in International Clinical Trials in Oncology 1993;85:365–76. 
 
14. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or 
partial credit. Psychol Bull 1968;70:213–20. 
 
15. Christie DRH, O’Brien MY, Christie JA. A comparison of methods of cosmetic assessment in breast 
conservation treatment. Breast 1996;5:358–67.  
 
16. Brunault P, Suzanne I, Trzepidur-Edom M, et al. Depression is associated with some patient-
perceived cosmetic changes, but not with radiotherapy-induced late toxicity, in long-term breast 
cancer survivors. Psychooncology 2013;22:590–7.  
 
17. Heil J, Dahlkamp J, Golatta M, et al. Aesthetics in breast conserving therapy: do objectively 
measured results match patients’ evaluations? Ann Surg Oncol 2011;18:134–8.  
 
35 
 
18. Yu T, Eom K-Y. Objective measurement of cosmetic outcomes of breast conserving therapy using 
BCCT.core. Cancer Res Treat 2015.  
 
19. Haviland JS, Sydenham M, Mills J, Hopwood P, Bliss JM, Yarnold JR. Can patient reported outcome 
measures replace clinical assessments in breast radiotherapy trials? Radiother Oncol 
2012;103:S53.  
 
20. Haloua MH, Krekel NMA, Jacobs GJA, et al. Cosmetic outcome assessment following breast-
conserving therapy: a comparison between BCCT.core software and panel evaluation. Int J Breast 
Cancer 2014;2014:1–7. . 
 
21. Hau E, Browne LH, Khanna S, et al. Radiotherapy breast boost with reduced whole-breast dose is 
associated with improved cosmesis: the results of a comprehensive assessment from the St. 
George and Wollongong randomized breast boost trial. Int J Radiat Oncol Biol Phys 2012;82:682–
9.  
22. Kelemen G, Varga Z, Lázár G, Thurzó L, Kahán Z. Cosmetic outcome 1–5 years after breast 
conservative surgery, irradiation and systemic therapy. Pathol Oncol Res 2012;18:421–7.  
 
 
 
 
 
 
 
 
 
 
 
36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
 
 
 
Chapter 3 
 
 
Predictors for poor cosmetic outcome in patients with early 
stage breast cancer treated with breast conserving therapy: 
Results of the Young boost trial 
 
 
 
 
 
 
 
Patricia J.A.M. Brouwers*, Erik van Werkhoven*, Harry Bartelink, Alain Fourquet, Claire Lemanski, 
Judith van Loon, John H. Maduro, Nicola S. Russell, Luc J.E.E. Scheijmans, Dominic A.X. Schinagl, 
Antonia H. Westenberg, Philip Poortmans, Liesbeth J. Boersma, on behalf of the Young Boost Trial 
research group 
* These authors contributed equally as the first author 
 
Radiother Oncol 2018: 128(3):434-441 
38 
 
Abstract  
Purpose: In the Young Boost trial (YBT), breast cancer patients ≤ 50 years of age, treated with breast 
conserving therapy (BCT) were randomized between a 26 Gy boost dose and a 16 Gy boost dose, with 
local recurrence as primary and cosmetic outcome (CO) as secondary endpoint. Data of the YBT was 
used to investigate which factors are related with worse cosmetic outcome after BCT.  
Methods: From 2004 to 2011, 2421 cT1-2N0-2a breast cancer patients were randomized. CO was 
scored subjectively by the patient and physician, and objectively using BCCT.core: at baseline, one and 
four years after treatment. Associations between potential risk factors for worse cosmetic outcome, 
based on the objective BCCT.core, were investigated using a proportional odds model.  
Results: At four years, CO was significantly better in the standard boost group for all three scoring 
methods (satisfied CO ±65% vs 55%).  A photon boost, high boost dose, poor cosmesis before radiation 
therapy, large boost volume and adjuvant chemotherapy significantly deteriorated CO. 
Conclusion: Important risk factors for worse CO were the use of a photon boost instead of an electron 
boost, a high boost dose, cosmesis at baseline, adjuvant chemotherapy and boost volume. These 
results can be used to define strategies aimed at improving CO. 
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Introduction  
In women with early breast cancer treated with breast-conserving surgery (BCS), whole breast 
radiation therapy (RT) reduces the risk of local recurrence at 5 years from 26% to 7%1. The EORTC 
“boost versus no boost” trial showed that an additional boost of 16 Gy to the tumour bed reduces the 
risk for local failure by a factor of 2, with an increased incidence of moderate/severe fibrosis as 
negative side effect2. However, after 10 years follow up, the risk of local failure remained unacceptably 
high, in the younger patients, even after a boost, with a risk of 13.5% in patients ≤40 years, and of 
8.7% in patients 41-50 years3. Therefore, in 2004, the Young Boost trial (YBT) was launched 
(NCT00212121) with the primary aim to investigate whether a higher boost dose of 26 Gy to the 
tumour bed would further reduce local recurrence rate in these young patients with cosmetic 
outcome as secondary endpoint. 
Several risk factors for deterioration of the cosmetic outcome have been described in literature, for 
example breast size4,5, tumour size6,7, excision volume6,7, tumour location5–7, post-operative 
complications4,5, boost volume8, a photon boost7,9, total dose10 and dose max8,9,11. However, no data 
is available concerning a boost dose as high as 76 Gy EQD2, which makes the YBT unique. Moreover, 
in order to be able to improve cosmetic outcome, we need to continue to update the knowledge of 
risk factors for cosmetic outcome with data derived from the most current literature.  
It was decided by the independent data monitoring committee that the primary endpoint (i.e. local 
failure) should not be analysed yet. However, they recommended that the cosmetic outcome, which 
was a secondary endpoint, could be analysed by treatment arm now that up to 4 years of follow-up is 
available. Previously, we reported that the distance from nipple to inframammary fold, the length of 
the breast contour and the severity of fibrosis were associated with patient reported outcome in the 
YBT12. The primary aim of this paper is to report on the cosmetic outcome in the YBT; the secondary 
aim is to define risk factors for worse cosmetic outcome in this patient population, based on the 
objective BCCT.core. 
 
Patients & Methods 
Patient population and treatment 
Patients younger than 51 years with non-metastatic, histological proven invasive breast cancer, pT1-
2N0-2a13 were eligible for the trial when fulfilling the following inclusion criteria:  ECOG performance 
scale  ≤ 2; wide local excision (WLE); microscopically complete (no tumour on ink) or focally involved 
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(defined as: ”tumour (ductal carcinoma in situ or invasive carcinoma) on ink in an area of less than 4 
mm”) resection; sentinel lymph node biopsy and/or axillary lymph node dissection; no primary 
systemic treatment; no previous history of malignant disease, except adequately treated carcinoma 
in situ of the cervix or basal cell carcinoma of the skin. Exclusion criteria were: residual 
microcalcifications on mammogram; histological other than invasive adenocarcinoma; in situ 
carcinoma of the breast without invasive tumour; multicentric tumours and multifocal tumours 
excised using multiple excisions; bilateral invasive breast cancer and concurrent pregnancy. More 
information can be found at https://clinicaltrials.gov/show/NCT00212121. 
Patients were randomized to receive a standard 16 Gy or a high 26 Gy boost to the tumour bed after 
50 Gy whole breast irradiation, given in 2 Gy fractions. Other fractionation schemes, including 
simultaneous integrated boost (SIB) techniques were allowed as well, as long as the biological 
equivalent dose (EQD2), calculated with an α/β of 10 for tumour control, was similar. The overall 
treatment time was kept constant in both randomization arms, i.e. 6.5-7 weeks (see supplementary 
file for more extensive information concerning the RT protocol). RT had to start within 10 weeks after 
surgery. In case adjuvant chemotherapy was given immediately after surgery, RT should start within 
6 months after surgery and within 6 weeks after the last cycle of chemotherapy. In case endocrine 
treatment was planned, this was recommended to start after completion of the RT. Stratification 
factors were age (<vs> 40 yrs.), pathological tumour size (<vs> 3 cm), oestrogen receptor status, nodal 
status, interstitial/external boost and institute. Patients were stratified at the time of randomization; 
treatment was assigned using a “randomization by minimisation” technique14. 
The study was centrally approved by the medical ethical committee of the Netherlands Cancer 
Institute and by the local medical ethical committees. All patients gave their written informed consent 
to participate. 
Recording of fibrosis and cosmetic outcome  
Cosmetic outcome and fibrosis were scored at baseline, i.e. after surgery but prior to start of RT, at 1 
year, 4, 7 and 10 years of follow up (FU). Standardized digital photographs were taken at the same 
time-points.  
The presence of fibrosis (whole breast and specifically in the boost area) was scored by the physician 
on a 4-point scale: none, minor, moderate or severe.  
Cosmetic outcome was scored according to the following three scoring systems: 
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BCCT.core software 15,16: digital photographs in anterior-posterior view were analysed using the 
BCCT.core software program. Pre-determined points were designated by the examiner, followed by 
an automatic calculation of an overall cosmetic score: excellent, good, fair or poor (score 1 to 4; higher 
score means worse outcome). This score is based on symmetry, skin colour and scar visibility.  
Physician’s score. Physicians scored cosmetic outcome using the Harris scale17: excellent, good, fair or 
poor, indicated as score 1 to 4 respectively. 
Patient’s questionnaire. Patients’ satisfaction with the cosmetic outcome was scored using a validated 
patient’s questionnaire developed by Sneeuw et al18: very satisfied, satisfied, not dissatisfied, 
dissatisfied or very dissatisfied (score 1 to 5 respectively).  
For the analyses of crude percentages, the scores very satisfied or satisfied and good or excellent were 
grouped as ‘satisfactory’.  
Analysis of risk factors for fibrosis and cosmetic outcome 
The following risk factors, scored on the Case Report Forms, were investigated: 
RT related risk factors: dose to the tumour bed; irradiated boost volume (per 10 cc), defined as the 
volume receiving more than 95% of the boost dose for external photon irradiation, and within 85% of 
the boost dose for electron and interstitial irradiation; photon boost versus electron boost; 
Simultaneous Integrated Boost (SIB) versus sequential boost; energy used for whole breast irradiation 
(WBI) and the use of CT-scan for planning. 
Systemic therapy related factors: adjuvant chemotherapy, adjuvant endocrine therapy. 
Surgery related factors: excision volume (per 10 cc); post-operative complications and seroma, scored 
as yes, no, or unknown. Postoperative complications were defined as the presence of infection and/or 
hematoma of breast and/or axilla. Oedema was not considered as a complication. Seroma was 
analysed separately from post-operative complications, as we assumed there might be a correlation 
with oncoplastic surgery.  
Tumour related factors: tumour location (lateral tumour location vs. central and medial/upper tumour 
location vs. central) (supplementary figure). 
Patient characteristics: age (per year) and cosmetic score at baseline.  
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Statistical analysis 
The percentages of patients with satisfactory cosmetic scores in the high- and standard boost group 
were compared at baseline, 1 year and 4 years with Fisher’s exact test. Associations between potential 
risk factors and cosmetic outcome, measured by BCCT.core, were assessed with a proportional odds 
model, in order to treat the cosmetic outcome as a variable with ordered categories. An important 
assumption of the proportional odds model is that the association between each pair of outcome 
groups is the same, so that for example the comparison between a score of 1 (=Excellent) versus a 
score of 2 (=Good), 3 (=Fair) or 4 (=Poor), and the comparison of 1 or 2 versus 3 or 4 can be modelled 
by the same parameter. The assumption was verified by calculation of linear predictions from a logit 
model, used to model the probability that the outcome is greater than or equal to a given value (for 
each cosmetic outcome level). These were compared between categories of one predictor variable at 
a time, and no great differences were observed.  
Both the number of patients with moderate and severe fibrosis, and of patients with severe fibrosis 
at baseline, 1 year, and 4 years was calculated as a percentage of the total number of patients with an 
assessment and compared by arm using Fisher’s test. Time to fibrosis was calculated from 
randomization to first reported occurrence of moderate or severe fibrosis. Patients with no or only 
minor fibrosis were censored at last follow-up. Risk factors for moderate or severe fibrosis were 
analysed with multivariable Cox proportional hazards models.  
 
Results 
Between 2004 and 2011, 2421 breast cancer patients were included in 32 institutes (18 from The 
Netherlands, 13 from France and 1 from Germany). 1211 patients were randomized to receive a 
standard 16 Gy boost and 1210 to receive a 26 Gy boost. Baseline patient characteristics were similar 
in both groups with the exception of boost technique (table 1). Median age was 45 years (range 19-
51), 19% was younger than 40 years of age. 72% of patients had a T1 tumour and 28% of patients had 
a T2 tumour. Median FU at the time of this analysis was 51 months. 46 patients did not comply with 
the inclusion criteria (supplementary file table A). All patients with available and evaluable digital 
photographs were included in the analysis.  
At baseline, 1657 evaluable digital photographs were available of the study population. At one year, 
evaluable digital photographs were available from 1455 patients, of whom 1276 also had an evaluable 
photograph at baseline. At four years, 684 digital photographs were evaluable of patients including a 
photograph at baseline (Fig. 1). 
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 Randomization treatment   
Patients 
16 Gy boost 
N=1211 
26 Gy boost 
N=1210 
Total 
N=2421 
P value 
Age at randomization  
Median age in years (range) 
 
45 (19-51) 
 
45 (21-51) 
 
45 (19-51) 
0.94 
Age (yrs) at randomization 
(grouped) 
19 - 24 
25 - 29 
30 - 39 
40 - 44 
45 - 59 
50 - 51 
 
1 (0%) 
15 (1%) 
219 (18%) 
348 (29%) 
516 (43%) 
112 (9%) 
 
2 (0%) 
13 (1%) 
223 (18%) 
351 (29%) 
512 (42%) 
109 (9%) 
 
3 (0%) 
28 (1%) 
442 (18%) 
699 (29%) 
1028 (43%) 
221 (9%) 
0.99 
 
 
 
 
 
 
Tumour location 
Central/lower 
Lateral 
Medial/upper 
NA 
 
275 (23%) 
606 (50%) 
323 (27%) 
7 
 
293 (24%) 
594 (49%) 
317 (26%) 
6 
 
568 (24%) 
1200 (50%) 
640 (27%) 
13 
0.69 
 
 
 
 
Pathological largest diameter (mm) 
N 
Median (range) 
 
1205 
15 (1-49) 
 
1201 
15 (1-95) 
 
2406 
15 (1-95) 
0.73 
 
 
Largest diameter (mm) (grouped) 
>20 mm 
≤20 mm 
NA 
 
345 (29%) 
860 (71%) 
6 
 
327 (27%) 
874 (73%) 
9 
 
672 (28%) 
1734 (72%) 
15 
0.47 
 
 
 
Excision volume (ml) 
N 
Median (range) 
 
1101 
112 (0-3150) 
 
1120 
105 (0-4462) 
 
2221 
108 (0-4462) 
0.19 
 
 
Final margin status 
Complete 
Focally incomplete excision 
 
1180 (97%) 
31 (3%) 
 
1182 (98%) 
28 (2%) 
 
2362 (98%) 
59 (2%) 
0.79 
Postoperative complications 
No 
Yes 
NA 
 
818 (68%) 
335 (28%) 
58 (5%) 
 
835 (69%) 
309 (26%) 
66 (5%) 
 
1653 (68%) 
644 (27%) 
124 (5%) 
0.29 
 
 
 
Endocrine therapy 
No 
Yes* 
NA 
 
483 (40%) 
667 (55%) 
61 (5%) 
 
491 (41%) 
650 (54%) 
69 (6%) 
 
974 (40%) 
1317 (54%) 
130 (5%) 
0.64 
 
 
 
Chemotherapy 
No 
Yes 
NA 
 
441 (36%) 
748 (62%) 
22 (2%) 
 
458 (38%) 
719 (59%) 
33 (3%) 
 
899 (37%) 
1467 (61%) 
55 (2%) 
0.37 
 
 
 
Timing of chemotherapy 
Prior to RT 
During RT 
After RT 
NA 
 
364 (49%) 
10 (1%) 
370 (49%) 
4 (1%) 
 
357 (50%) 
   2 (0%) 
356 (50%) 
 4 (1%) 
 
721 (49%) 
12 (1%) 
726 (49%) 
8 (1%) 
0.08 
Radiation quality 
Cobalt60 
X-ray beams 
 
0 (0%) 
1196 (99%) 
 
3 (0%) 
1180 (98%) 
 
3 (0%) 
2376 (98%) 
0.12 
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NA 15 (1%) 27 (2%) 42 (2%)  
 
X-ray energy (MV) WBI 
N 
Median (range) 
 
1086 
6 (4-25) 
 
1055 
6 (4-25) 
 
2141 
6 (4-25) 
0.95 
 
 
Irradiated boost volume (cc) 
N 
Median (range) 
 
1125  
135 (0-1125) 
 
1106  
130 (0-1308) 
 
2231 
132 (0-1308) 
0.08 
 
 
Boost technique 
Electrons 
Cobalt60 
Photons 
Interstitial boost 
Other/NA 
 
 
265 (22%) 
6 (0%) 
882 (73%) 
10 (1%) 
48 (4%) 
 
 
214 (18%) 
4 (0%) 
895 (74%) 
13 (1%) 
84 (7%) 
 
 
479 (20%) 
10 (0%) 
1777 (73%) 
23 (1%) 
132 (5%) 
 
0.04 
 
 
 
 
 
 
SIB 
No 
Yes 
NA 
 
784 (65%) 
416 (34%) 
11 (1%) 
 
768 (65%) 
416 (34%) 
26 (2%) 
 
1552 (64%) 
832 (34%) 
37 (2%) 
0.83 
 
 
 
Planning CT** 
No 
Yes 
NA 
 
286 (24%) 
917 (76%) 
8 (1%) 
 
291 (24%) 
902 (75%) 
17 (1%) 
 
577 (24%) 
1819 (75%) 
25 (1%) 
0.74 
 
 
 
 
Table 1. Patient and treatment characteristics at baseline.  
Abbreviations: NA = not applicable; RT = radiotherapy; WBI = whole breast irradiation; MV = 
megavolt; SIB = simultaneous integrated boost.   
* in 85% Tamoxifen 
** If 3D planning and 3D delineation was performed 
 
At baseline, cosmetic score was similar in both patient groups independent of the scoring-methods. 
In 90% cosmetic score was satisfactory based on BCCT.core. According to the physician or patient, 
satisfactory scores were 80% or a little less than 70% respectively, at baseline. At 4 years, cosmetic 
outcome was significantly worse than at baseline in both treatment arms, for all three scoring-
methods.   The cosmetic outcome was better in the standard boost group compared to the high boost 
group for all three scoring-methods: according to BCCT.core 67% of patients had satisfactory cosmesis 
in the standard boost, versus 55% in the high boost group (p=0.0009). For scores by the physicians 
these numbers were 65% and 52% (p<0.0001), and for patients 63% and 53% (p=0.0007), respectively 
(Table 2). 
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Figure 1. Flow diagram of available and evaluable digital photographs per July 2014, and completed 
Case Report Form (CRF) and completed patient questionnaires of all institutes per February 2017. 
 
At 4 years, the physician scored moderate or severe fibrosis in the boost area in 159 patients (19%) in 
the standard boost group versus 332 (39%) in the high boost group (p<0.0001). Severe fibrosis was 
scored in the boost area in 25 (3%) and 89 (11%) patients in the standard and high boost group, 
respectively (p<0.0001) (Table 2). Also, when fibrosis was calculated as a percentage of the evaluable 
patients at the three time points separately, the difference between the arms remained significant 
(Table 2).   
The cumulative incidence of moderate or severe fibrosis in the boost area at 4 years was 27% (95%CI 
24%–30%)in the s boost group versus 45% (95% CI 42–47%) in the high boost group (p<0.0001, Fig. 2).  
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Figure 2. Cumulative incidence of moderate or severe fibrosis in the boost area 
 
 
There was a low correlation between cosmetic outcome and fibrosis: Spearman's rank correlation 0.29 
(p<0.0001). 
Significant risk factors in the multivariable model for worse cosmetic outcome according to BCCT.core 
score at 4 years were a photon boost (odds ratio 1.98 compared to electrons), a high boost dose (odds 
ratio 1.82 compared to standard boost), cosmesis at baseline (odds ratio 1.80 per BCCT.core category), 
adjuvant chemotherapy (odds ratio 1.58 yes vs. no) and boost volume (odds ratio 1.04 per 10 cc). The 
following factors were not significantly associated with cosmetic outcome: age, tumour location, 
adjuvant endocrine therapy, radiation energy WBI, use of CT for planning, excision volume per 10 cc, 
postoperative complications, seroma or whether the boost was given simultaneously (SIB) versus 
sequentially (Table 3). Significant risk factors for moderate or severe fibrosis were cosmesis at baseline 
(HR 1.20 per BCCT.core category), a high boost dose (HR 2.00), age (HR 1.02 per year older), adjuvant 
chemotherapy (HR 1.25 yes vs. no), radiation energy WBI (HR 1.03 per MV), irradiated boost volume 
(HR 1.01 per 10cc) and a simultaneous integrated boost (HR 1.40 yes vs. no) (Table 4).  
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 Odds ratio 95% CI P value 
Cosmesis at baseline 1.80 1.40 – 2.33 <0.0001 
High boost dose 1.83 1.33 – 2.54 <0.0001 
Age (per year) 0.99 0.96 – 1.02 0.557 
Lateral tumour location vs. central 0.70 0.47 – 1.03 0.073 
Medial/upper tumour location vs. 
central 
0.83 0.53 – 1.31 0.429 
Adjuvant chemotherapy 1.53 1.04– 2.27 0.032 
Adjuvant endocrine therapy 1.16 0.80 – 1.69 0.429 
Photon energy of WBI 1.05 0.97 – 1.13 0.232 
Boost volume per 10 cc* 1.04 1.02 – 1.05 <0.0001 
Boost technique (photon vs. electron) 1.98 1.31 – 3.01 <0.0001 
SIB vs. sequential boost 0.96 0.63 – 1.46 0.837 
Seroma 1.52 0.93 – 2.50 0.097 
Postoperative complications 1.15 0.78 – 1.70 0.478 
Excision volume per 10 cc 1.00 1.00 – 1.01 0.448 
Use of planning CT 0.90 0.62 – 1.31 0.585 
 
Table 3. Results of the multivariable proportional odds model for cosmetic outcome based on 
BCCT.core. Odds ratio > 1 means that the factor as a negative impact on cosmetic outcome, < 1 a 
positive impact. 
* The irradiated boost volume is defined as the volume receiving more than 95% of the boost dose 
for external photon irradiation, and within 85% of the boost dose for electron and interstitial 
irradiation. 
WBI = whole breast irradiation. SIB = simultaneous integrated boost. 
 
Discussion  
The results of this analysis demonstrate that, as expected, a high boost causes a less satisfactory 
cosmetic outcome.  At 4 years follow up, the percentage of patients with a satisfactory cosmetic 
outcome was about 10% lower in the high boost group compared to the standard boost group, 
whichever scoring method (BCCT.core, physician, or patient herself) was used. Also, in the high boost  
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 HR 95% CI P value 
Cosmesis at baseline 1.20 1.06 – 1.35 0.003 
High boost dose 2.00 1.71 – 2.35 <0.0001 
Age at randomization 1.02 1.01 – 1.04 0.005 
Lateral tumour location vs. central 0.98 0.80 – 1.19 0.081 
Medial/upper tumour location vs. 
central 
1.16 0.94 – 1.44 0.17 
Adjuvant chemotherapy 1.25 1.04– 1.51 0.017 
Adjuvant endocrine therapy 0.97 0.81 – 1.15 0.72 
Photon energy of WBI 1.03 1.01 – 1.06 0.007 
Boost volume per 10 cc* 1.01 1.01 – 1.02 <0.0001 
Boost technique (photon vs. electron) 1.13 0.90 – 1.40 0.30 
SIB vs. sequential boost 1.40 1.16 – 1.71 0.0006 
Seroma 1.19 0.96 – 1.47 0.11 
Postoperative complications 1.05 0.87 – 1.27 0.62 
Excision volume per 10 cc 1.00 1.00 – 1.00 0.28 
Use of planning CT 0.89 0.73 – 1.10 0.28 
 
Table 4. multivariable model of time to moderate or severe fibrosis in the boost area. 
* The irradiated boost volume is defined as the volume receiving more than 95% of the boost dose 
for external photon irradiation, and within 85% of the boost dose for electron and interstitial 
irradiation. 
WBI = whole breast irradiation. SIB = simultaneous integrated boost. 
 
group twice as much moderate or severe fibrosis was scored at 4 years. The multivariable model 
showed that other important risk factors for worse cosmetic outcome were the use of a photon boost, 
cosmesis at baseline, adjuvant chemotherapy and boost volume. It is important to note that we have 
reported the estimate of the effect of the boost volume as a continuous variable per 10 cc. This means 
that the odds ratio holds for every increase of 10 cc. The odds ratio is 1.48 if the boost volume is 
considered per 100 cc.  
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Risk factors for moderate or severe fibrosis consisted of the same risk factors as for worse cosmetic 
outcome with the exception of a photon boost and supplemented with age, photon energy of WBI en 
a simultaneous integrated boost technique.  
Although a worse cosmetic outcome was expected for the high boost arm, we surprisingly also 
observed a somewhat worse cosmetic outcome in the standard boost arm, compared to the identical 
16 Gy boost arm in the former boost versus no-boost trial10. In the latter trial, the panel evaluation at 
3 years showed that 71% of patients in the boost group had an excellent or good global result, which 
is better than the 65% satisfactory score by the physicians that we found in the 16 Gy boost arm. There 
are several possible explanations for this difference. First, in the majority of cases in the boost versus 
no-boost trial, the boost dose was given with electrons (74.9% )7; whereas a photon boost was the 
most important risk factor in our model. Second, in the YBT only the treating physician scored the 
cosmesis, in contrast to the boost vs no-boost trial, where cosmetic outcome was scored by a panel. 
Third, in the YBT timing of scoring was one year later (at four instead of three years follow up); the 
boost vs. no-boost trial already showed that asymmetry progressed over years7. Fourth, in the YBT, a 
larger amount of patients underwent chemotherapy. In the boost no-boost only 10% of patients 
received chemotherapy, in the YBT this percentage was 60% and chemotherapy was identified as a 
risk factor for worse cosmetic outcome in our model. Finally, also the boost volume was different. Al 
Uwini et al already showed an enlargement of boost volumes by using a planning CT19. He recalculated 
the boost volumes of the boost versus no-boost trial and showed that the volume of the 95% dose 
level was larger in the YBT. Surprisingly, use of a planning CT was not an independent risk factor in our 
model, but there might be interaction with the volume variable.  
Previous studies found various risk factors for worse cosmetic outcome or fibrosis. Cosmetic outcome 
and fibrosis are both late toxicity endpoints and are probably associated with each other, but show 
different progression in time. Where fibrosis is most progressive in the first three to four years9, 
cosmetic deterioration progresses further over the years, also resulting from increasing asymmetry 
following more pronounced changes in the non-treated breast with ageing7. The results in literature 
are difficult to interpret due to different outcome measures including fibrosis and cosmetic outcome 
(automatic photograph based, patient score, panel or physician score) and different duration of follow 
up. Nevertheless, all various risk factors can be brought together to some overarching risk factors: 1. 
Dose homogeneity (IMRT20, Dmax8,9,11, V55Gy11, V11021, V1074, breast size4,5, prone/supine22); 2. Total 
dose (hypofractionation23,24, boost no-boost10, Young Boost); 3. Boost volume8 (excision volume6,7, 
tumour size6,7, photon boost7,9, re-excision25, time between surgery and RT, oncoplastic surgery26) and 
4. Baseline cosmesis (excision volume6,7, tumour size6, location of tumour5–7, post-operative 
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complications4,5). Further, adjuvant chemotherapy might result in worse cosmesis6,25,27. However, 
nowadays, many patients receive primary chemotherapy and one can assume this beneficially 
influences cosmetic result by decreasing tumour size, resulting in smaller excision volumes (better 
baseline cosmesis).  
We were somewhat surprised to find SIB as a risk factor for moderate or severe fibrosis, as several 
planning studies showed dosimetric advantage 28. To our knowledge, only the group of Groningen 
published data concerning fibrosis in a large cohort of breast cancer patients treated with a photon 
SIB 11,25. They found moderate or severe fibrosis in maximal 13.4% of patients, compared to the 22% 
(data not shown) we found in our standard boost arm (SIB), but they did not compare it with 
sequential boost results. One explanation might be that the fraction size to the boost volume was 
higher with the SIB than with the sequential boost, resulting in a higher EQD2 (67.6 vs 66 Gy, and 78.5 
Gy vs 76 Gy for an α/β ratio of 4 Gy, and 68.2 Gy vs 66 Gy and 79.5 Gy vs 76 Gy vs for an α/β ratio of 3 
Gy.   
Unfortunately, we did not score whether oncoplastic surgery had been performed. The obvious aim 
of oncoplastic surgery is to improve cosmetic outcome. However, after oncoplastic breast surgery the 
definition of the tumour bed could be more difficult, because of large mammary gland translations, 
rotations or excisions. Therefore, tumour bed delineation after oncoplastic surgery will be difficult, 
especially without surgical clips29, which can lead to larger boost volumes30. Close collaboration 
between surgeon and radiation oncologist could lead to a reliable, compact boost volume after 
oncoplastic surgery (mark lumpectomy cavity, then approximate lumpectomy cavity, then apply 
oncoplastic manoeuvres). The challenge for the future is to find an accurate balance between the 
extent of oncoplastic surgery and the following uncertainties for the radiation oncologist31.   
It could have been interesting to analyse the impact of the timing of chemotherapy on cosmetic 
outcome. We tried to analyse this in the multivariable model by putting chemotherapy into the model 
as a variable with three categories: chemotherapy before RT, after RT and no chemotherapy at all. 
This showed that compared to no chemotherapy at all, chemotherapy before RT was significantly 
associated with worse cosmetic outcome, but not if the chemotherapy was given after RT (results not 
shown). In order to clarify this discrepancy, we looked within the subgroup of patients with 
chemotherapy. In that subgroup, there was no difference between before and after, whether we 
corrected for the other clinical variables in the model or not. Therefore, we believe that we do not 
have sufficient power to draw valid conclusions about the impact of the timing of chemotherapy.  
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The Young Boost Trial is a large international randomized trial and by our knowledge the only trial to 
investigate the influence of such a high boost dose (EQD2 76 Gy) on cosmetic outcome. Nevertheless, 
there are some limitations to mention. First of all, we were unable to test all the now known risk 
factors, such as for example smoking and breast size, since these factors were not known during the 
design of the YBT. Further, as we described in the methods section, the study was designed with an 
α/β of 10 for tumour control, which was a logical assumption at that time. However, the START trials 
has shown an α/β value for locoregional relapse of 3.5 Gy23.The results of the YBT provide better 
perception of the risk factors for worse cosmetic outcome. These data therefore provide valuable 
tools when developing a strategy to improve cosmetic outcome. Since boost dose was one of the most 
important risk factors predicting poor cosmetic outcome, and local control has increased considerably 
in the last decade32,33, we advise to critically re-evaluate the indication for a (high) boost. Whenever a 
boost is indicated, an electron boost might be preferred, on the condition that the boost volume is 
delineated (instead of virtual simulation). Further, the size of the boost volume should be limited as 
much as possible, by using all available pre- and post-operative data31,34. How to take into account 
baseline cosmetic score is however puzzling: one may argue that oncoplastic surgery will improve 
cosmetic outcome, since a good baseline cosmesis is correlated with a better cosmetic outcome; 
however, some studies also suggest that oncoplastic surgery leads to a worse cosmetic outcome26, 
possibly as a consequence of the resulting larger boost volumes combined with more tissue damage 
due to extended devascularisation of the intramammary tissue flaps. The most important issues that 
need further studies are both the influence of extensive oncoplastic surgery and the influence of 
primary chemotherapy on cosmetic outcome.  
 
Conclusion 
The 4 year results of the YBT show that a photon boost, a high boost dose, poor cosmesis before RT, 
large boost volume, and adjuvant chemotherapy result in worse cosmetic outcome. These data offer 
valuable tools to develop strategies aimed at improving cosmetic outcome. 
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Supplementary figure. Tumour location.  
The number represents the dominant location of the lesion. We lumped several regions together to 
create the different tumour locations: central under, lateral en medial upper.  
Central under: 13, 14, 15 and 18 (right breast) and 23, 24, 25 and 28 (left breast). 
Lateral: 11 and 19 (right breast) and 21 and 29 (left breast). 
Medial-up: 12, 16 and 17 (right breast) and 22, 26 and 27 (left breast). 
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N  Major protocol 
violation 
N  Minor protocol 
violation 
N  Unknown major / 
minor protocol 
violation 
Total 
4 higher tumour stage 
than allowed 
12 informed consent was 
received too late 
4 released by the 
investigator without 
giving a reason 
 
2 residual 
microcalcifications on 
the post-operative 
mammography 
6 delay in start of 
radiation therapy 
after surgery 
8 no reason was given of 
why inclusion criteria 
were not met 
 
 
3 mastectomy 1 51 years old    
2 different pathology      
1 withdrawn on patients’ 
consent 
     
1 multifocal tumour      
1 no baseline photograph      
1 neoadjuvant 
chemotherapy 
     
       
15  19  12  46 
 
Supplementary file table A. Protocol violations. The investigators were asked whether or not 
inclusion criteria were met. Not always a reason was given why inclusion criteria were not met (last 
column).  
Only patients with available digital photographs were included in the analysis.  
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Abstract 
Purpose: To compare set-up and 2-dimensional (2D) electronic portal imaging device (EPID) dosimetry 
data of breast cancer patients treated during voluntary moderately deep inspiration breath hold 
(vmDIBH) and free breathing (FB). 
Methods and materials: Set-up data were analysed for 29 and 51 consecutively treated patients, 
irradiated during FB and vmDIBH, respectively. Of the 51 vmDIBH patients, the first 25 had undergone 
an extra trained computed tomography (CT) scan and used an additional “breathing stick” 
(vmDIBH_trained). The last 26 patients did not use the breathing stick and did not undergo a trained 
CT (vmDIBH_untrained). The delivered 2D transit dose was measured with EPID in 15 FB and 28 
vmDIBH patients and compared with a 2D predicted dose by calculating global gamma values γ using 
5% and 5 mm as dose difference and distance-to-agreement criteria, respectively. Measurements with 
a percentage of pixels with an absolute gamma value >1 (|γ| > 1) greater than 10% were classified as 
deviating. 
Results: Only small, sub-millimeter differences were seen in the set-up data between the different 
patient groups. The mean of means, systematic error, and random error ranged from -0.6 mm to 3.3 
mm. The percentage of pixels with |γ| > 1 for all patients was 9.8% (2-25.8). No statistically significant 
differences were observed between the patient groups. In total, 38% of the gamma images were 
classified as deviating: 43.6% in vmDIBH_untrained patients compared with 38.0% in vmDIBH_trained 
patients and 33.3% in FB patients (P>0.05). 
Conclusion: Both set-up and 2D EPID dosimetry data indicate that reproducibility of radiation therapy 
for patients treated during FB and vmDIBH is similar. Small but not significant differences in 2D EPID 
dosimetry were observed. Further investigation with 3-dimensional EPID dosimetry is recommended 
to investigate the clinical relevance of deviant gamma images. 
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Introduction 
The conventional technique of breast and thoracic wall irradiation is by tangential fields, implicating 
that the heart and lungs can be partially located within the radiation field. Several reports have shown 
that heart irradiation may lead to late cardiac toxicity1. In addition, several articles report that lung 
injury occurs from breast irradiation, although the incidence of clinically relevant radiation 
pneumonitis is fortunately quite low2. 
In the literature, a significantly increased risk of cardiac death has been observed for patients treated 
with left-sided breast cancer 20-30 years ago3. The incidence of cardiac injury using modern radiation 
therapy techniques is not completely clear, however. Although Offersen et al4 described several 
uncertainties with respect to parameters related to radiation-induced heart injury, it seems clear that 
both radiation dose and volume play an important role in the development of both heart and lung 
toxicity. Consequently, reducing both irradiated volume and dose to the heart and lung is expected to 
reduce heart and lung toxicity. 
Multiple respiratory techniques have been described to spare both heart and lung, taking into account 
that during deep inspiration the heart moves out of the radiation field and the relative volume of 
irradiated lung is reduced. This can be achieved using voluntary breath hold techniques5-8, an Active 
Breathing Control (ABC) device9 or gating7,10. For the latter 2, additional equipment is required, 
whereas the voluntary method appears to be easy and inexpensive. However, concerning voluntary 
breath hold, reproducibility is often questioned. Only a limited number of studies5,11-13 analysed set-
up in breath hold, but none of these studies reported actual measured transit dose for verification. 
The aim of this article is to investigate whether the reproducibility of voluntary moderately deep 
inspiration breath hold (vmDIBH) is similar to free breathing (FB) by reporting set-up and 2-
dimensional (2D) EPID dosimetry data, acquired during the development of the vmDIBH technique in 
our institute. 
 
Methods and materials 
Patients 
In our institute, vmDIBH was implemented in 2005. In 2008, we started a step-by-step process to 
simplify the logistics, that is, 2 computed tomography (CT) scans on 1 day, instead of 3 CT scans in 2 
days, as described later. Data were obtained in 80 consecutive breast cancer patients, treated in a  
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Figure 1 Schematic overview of number of patients and available data. 
 
 
fixed period between October 2008 and October 2009 (Fig 1). During the period of the simplification 
process, 3 treatment groups could be distinguished: 
1) Control group (ie, FB patients; N = 29). 
2) vmDIBH patients with 3 CT scans and using an additional aid called the “breathing stick” (N = 25), 
developed to assist patients to achieve a reproducible breath hold (Fig 2). These patients first 
underwent 2 planning CT scans: 1 during FB and 1 during untrained vmDIBH9. Both scans were 
compared, and if the maximum heart distance (MHD, Fig 3) was ≥1 cm in the FB scan and <1 cm 
in the vmDIBH, it was decided to treat the patient during breath hold. The patient was then 
phoned and asked to practice the breath hold at home, using written breath-hold instructions. 
After practicing breath hold at home, a third, trained vmDIBH CT scan was obtained, which was 
used for treatment planning. 
3) vmDIBH patients with only 2 untrained CT scans and without the breathing stick (N = 26). To 
investigate whether omitting the third CT scan would be safe, we performed an “interim in-silico” 
comparison in 10 patients of group 2: the digitally reconstructed radiographs (DRRs) for the 
tangential fields of the untrained vmDIBH CT scan were compared with the DRRs of the trained 
vmDIBH CT scan. We found a small set-up difference, manageable by our set-up protocol, but no 
clinically relevant difference was seen in the MHD (mean difference 0.3 mm ± 1.8). Based upon 
this analysis, we decided to omit the third trained vmDIBH CT scan, and used the untrained 
vmDIBH CT scan for treatment planning. At the same time, we omitted the breathing stick.  
 
Number of  
patients 
N=80 
Free Breathing  
( FB ) 
N=29 
Set-up data available 
N=29 
voluntary  
moderately Deep  
Inspiration Breath  
Hold (vmDIBH) 
N=51 
EPID dosimetry 
available 
N=12 (48%) 
Set-up data available 
with a trained CT and   
breathing stick 
N=25 
EPID dosimetry  
available 
N=15 (52%) 
Set-up data available 
with an untrained CT  
and without breathing  
stick  
N=26 
EPID dosimetry  
available 
N=16 (62%) 
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Figure 2 (A) The “breathing stick” that was placed on the skin of the patient outside the radiation 
fields in the epigastric area during breath hold and (B) an integrated ruler. The contact point of the 
tip of the ruler was marked by a dot on the skin during the third computed tomography scan in 
voluntary moderately deep inspiration breath hold (vmDIBH). During treatment, the radiation 
technician could check visually, and the patient could feel, whether the tip of the stick made contact 
at the dot on the skin, ensuring a correct breath hold. 
 
Methods 
CT scanning and treatment planning 
Patients were scanned in the supine position with the arms above the head in an arm support (Civco, 
Posirest-2, USA), and the legs resting on a Kneefix (Civco). All CT scans were obtained with 3-mm slice 
thickness from the level of the mandible down to the diaphragm (Siemens Somatom Sensation). 
Treatment planning was performed using forward intensity modulated radiation therapy planning as 
described earlier14. The target volume consisted of the breast or thoracic wall with or without regional 
lymph nodes. 
Set-up verification 
A shrinking action level protocol was used for set-up verification, with α = 10 and n = 315 for all patients. 
Four skin markers were placed onto the skin at the medial, lateral, cranial, and caudal edges of the 
breast or thoracic wall. Both lateral and anteroposterior electronic portal images (EPIs) were matched 
to the DRRs using both anatomy and skin markers16. 
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Differences between the EPIs and the DRRs were analysed in 3 directions: left-right, craniocaudal, and 
anteroposterior. The mean of means (μ) was determined by calculating the average of the individual 
systematic set-up errors for all patients. The systematic set-up error for the population (Σ) was 
calculated by taking the standard deviation of the individual systematic set-up errors for all patients. 
The random set-up error of the population (σ) was calculated by taking the average of the individual 
random set-up errors for all patients17. 
 
 
Figure 3. The maximum heart distance is the maximum distance between the heart contour and the 
posterior field border of a tangential treatment beam. (A) In free breathing, the heart is partially 
located within the radiation field; (B) in voluntary moderately deep inspiration breath hold (vmDIBH), 
the heart moves out the radiation field. 
 
 
Dose verification 
According to the clinical protocol, 2D transit dose distributions were measured during the first 3 
fractions, thereafter weekly, using EPIs. OptiVue 500/1000/1000 ST amorphous silicon flat panel 
portal imagers (Siemens Medical Solutions, Concord, CA), attached to Oncor medical linear 
accelerators (Siemens Medical Solutions), were used for these measurements. The measured 
delivered transit dose was compared with a predicted dose by calculating global gamma values using 
5% and 5 mm as dose difference and distance-to-agreement criteria18. The percentage of pixels with 
an absolute gamma value >1 (|γ| >1) was determined only for lateromedial and mediolateral beams. 
Median values of this parameter were compared among the 3 patient groups. Measurements with a 
percentage of pixels |γ| >1 greater than 10% were classified as deviating. Deviant gamma images were 
inspected visually. Only if 1 part of the image showed clear underdosage and the other part showed 
clear overdosage, the dose difference was considered to be due to a simple translation (set-up 
error/organ motion); if the gamma image showed other patterns of over- and/or underdosage, the 
67 
 
dose difference was considered to be due to rotation, change in breast shape or a combination of both 
(Fig 4). 
Because the treatment fields did not always fit within the field of view of the flat panel portal imagers, 
EPID dosimetry data could not be evaluated for all patients. In total, 241, 590, and 565 measurements 
were obtained for 15 FB, 12 vmDIBH patients with trained CT, and 16 vmDIBH patients with an 
untrained CT, respectively (Fig 1). 
 
 
Figure 4. Examples of gamma images of a tangential breast field. Red and blue colors represent regions 
where the measured dose is higher or lower than planned, respectively, whereas green represents 
regions where the planned and measured dose are in agreement. (A) A typical simple translation and 
(B) an example of rotation or changes in breast shape. 
 
Analysis and statistics 
Set-up data were analysed and compared for the 3 treatment groups: 25 vmDIBH patients treated 
with trained CT (vmDIBH_trained), 26 vmDIBH patients without trained CT (vmDIBH_untrained), and 
29 FB patients. Mean of means, random error, and systematic error of the vmDIBH patients were 
calculated for this purpose. In addition, the number of measurements and applied set-up corrections 
was counted for the 3 treatment groups. The percentage of deviant measurements and of dose 
differences interpreted as from a translation were compared between the patient groups. We were 
particularly interested in translations, because we assumed that a change in breath hold would likely 
show up as translations. In all analyses, the Kruskal-Wallis test was used with p <0.05 as the level of 
significance. In case of a significant difference, a Mann–Whitney test was used for detailed analysis. 
Median results are noted with range in parentheses. 
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Results 
Patient characteristics are listed in Table 1. All vmDIBH patients had left-sided breast cancer, with an 
assumed benefit from vmDIBH, based upon a reduction of the maximum heart distance (Fig 3). FB 
patients had right or left-sided breast cancer, assuming that laterality does not influence set-up 
accuracy. In 1 patient, vmDIBH was not feasible because of shortness of breath; in all other patients, 
vmDIBH had no added value. 
 
 
 Median age  
and range 
Type of surgery 
Mastectomy 
Breast conserving 
surgery 
Free breathing 64 (42-83) 9 20 
vmDIBH_trained 53 (41-68) 4 21 
vmDIBH_untrained 51 (37-70) 2 24 
 
Table 1. Patient characteristics 
FB = free breathing; vmDIBH = voluntary moderately deep inspiration breath hold. 
Using the Kruskal-Wallis test, age of FB patients is significantly higher than both vmDIBH patient 
groups (p <0.001). Although a clear trend is seen, type of surgery is not significantly different (chi-
squared test: p > 0.05). 
 
 
Analysis of set-up data 
The systematic error in all patients varied between 1.2 and 2.0 mm; the random error between 2.2 
and 3.3 mm. Mean of means varied between −0.6 and 0.9 mm (Table 2). The random error showed a 
significant difference in craniocaudal direction for FB compared with vmDIBH_ trained, whereas the 
mean of means showed a significant difference in the anteroposterior direction for FB compared with 
vmDIBH_trained and vmDIBH_untrained. Although the number of measurements for 
vmDIBH_untrained was larger than for FB patients (p = 0.03), the number of set-up corrections was 
similar (p < 0.2) (Table 3). 
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 Mean of means μ (mm) Systematic error Σ (mm) Random error σ (mm) 
 LR CC AP LR CC AP LR CC AP 
All patients  
(N = 80) 
0.4 0.7 -0.0 1.7 1.6 2.0 2.8 2.7 3.2 
FB  
(N = 29) 
0.2 0.7 0.7 2.0 1.6 2.0 2.9 2.2 3.1 
vmDIBH_trained  
(N = 25) 
0.4 0.6 -0.3 1.2 1.9 2.0 2.8 3.0 3.1 
vmDIBH _untrained  
(N = 26) 
0.6 0.9 -0.6 1.7 1.4 1.9 2.6 3.0 3.3 
p value 0.7 0.9 0.04    0.7 0.01 0.8 
 
Table 2. Set-up data of all patients and subdivided by treatment group  
AP: anteroposterior; CC: craniocaudal; FB: free breathing; LR: left-right; vmDIBH: voluntary 
moderately deep inspiration breath hold.            
Using a Kruskal-Wallis test, significant differences were found in mean of means (AP) and random 
error (CC) among the 3 groups. Detailed analysis using a Mann–Whitney test showed a significant 
difference in mean of means in AP direction between FB and vmDIBH_untrained (p = 0.02) and in 
random error in CC direction between FB and vmDIBH_trained and vmDIBH_untrained (p < 0.02). 
 
Analysis of 2D EPID dosimetry data 
The median percentage of pixels with |γ| > 1 for all patients was 9.8% (2-25.8%) (Table 4). The 
percentage of deviating images was somewhat higher in vmDIBH patients (vmDIBH_trained (38%) and 
vmDIBH_untrained (43.6%)) than in FB (33.3%), but the difference was not statistically significant. 
Visual inspection of deviant gamma images showed no significant difference in the percentage of 
deviating gamma images attributed to translation in vmDIBH_trained, vmDIBH_untrained, and FB 
patients (14.9% [0-66.6%], 12.7% [0-83.3%], and 0 [0-100%], respectively). No differences were seen 
between mediolateral and lateromedial beams (all p > 0.3). 
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 Median no. of measurements 
(range) 
Median no. of corrections 
(range) 
Free breathing 8 (4-12) 1 (0-4) 
vmDIBH_trained 9 (4-18) 1 (0-7) 
vmDIBH_untrained 10 (5-16) 1 (0-4) 
 
Table 3. Median numbers of set-up measurements and median number of corrections per patient for 
the 3 patient groups FB = free breathing; vmDIBH = voluntary moderately deep inspiration breath 
hold. 
Comparing the 3 groups with the Kruskal-Wallis test, vmDIBH_untrained patients had a larger number 
of set-up measurements than FB patients (p = 0.03). However, the number of corrections per patient 
was similar for the 3 patient groups (p > 0.2). 
 
Discussion 
To our knowledge, this is the first article reporting on both set-up and in vivo dosimetric data obtained 
during vmDIBH. Although the dosimetry data showed remarkably large deviations, differences in set-
up errors between FB and vmDIBH were extremely small (sub-millimeter) and comparable with data 
reported earlier in FB patients19,20. Therefore, we consider vmDIBH to be as reproducible as standard 
FB techniques. Furthermore, we showed that by careful step-by-step introduction of vmDIBH, an easy, 
widely applicable procedure can be obtained. 
Comparison with literature 
Set-up data specific for vmDIBH are sparsely available in literature. Lu et al performed repeated CT 
scans and showed that all patients (N = 15) except 1 reasonably reproduced their position between 
different breath-holding cycles7. The Netherlands Cancer Institute described set-up data in patients 
during radiation therapy in DIBH. Set-up deviations (systematic error) in the order of 1.4-2.9 mm13, ≤ 
1.7 mm11, and ≤1.4 mm were reported12, which are comparable with the 1.2-2 mm found in the 
current study. 
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Median % of pixels with 
|y| > 1 per patient 
and range 
Median % of 
deviating 
measurements 
and range 
Median % of 
deviating measurements 
resulting from a translational 
set-up error and range 
All patients together 
N = 1396 
9.8 (2.0-25.8) 38.0 (4.2-81.3) 13.7 (0-100) 
Free breathing 
N = 241 
8.2 (2.0-25.0) 33.3 (7.1-64.3) 0.0 (0-100) 
vmDIBH _trained 
N = 590 
10.7 (2.3-21.6) 38.0 (4.2-72.0) 14.9 (0-66.6) 
VmDIBH _untrained 
N = 565 
12.3 (4.8-25.8) 43.6 (12.5-81.3) 12.7 (0-83.3) 
 
   
Table 4. Analysis of 2D EPID dosimetry data 
No significant differences were found (p > 0.3, Kruskal-Wallis test). 
 
Theoretically, one would assume that ABC (i.e. breath hold with an additive device) results in better 
set-up reproducibility. This assumption, however, is not confirmed in the literature9,21,22. Recently, the 
results of the UK HeartSpare Study were published and suggest that ABC and vmDIBH are comparable 
both in terms of positional reproducibility and normal tissue sparing. In addition, patients experience 
vmDIBH more comfortably than with an ABC23. 
Although our set-up errors were reasonably small and comparable to literature, the measured dose 
showed remarkably large deviations (i.e. > 10% pixels with |γ| > 1), both for vmDIBH and for FB 
patients. The clinical relevance of these deviations in 2D dosimetry is still unclear. To our knowledge, 
only Fidanzio et al24 published results of breast in vivo dosimetry using EPID, but they did not take into 
account the entire tangential field. They determined the ratio between reconstructed and planned 
dose at breast midpoint, thus verifying a point dose in the patient and not a 2D transit dose 
distribution at the EPID plane. When patient set-up variations were not taken into account, these 
ratios were within 5% in 72% of the checks. Because no comparable dosimetry data are available in 
the literature and because our set-up data are comparable to those reported in literature, we assume 
that these dosimetry results would be found in other institutes as well, if measured. This assumption 
is supported by the article by Topolnjak et al25, who showed that set-up verification easily lead to large 
differences between predicted and measured transit dose. The latter could also be an explanation for 
the, although not statistically significant, differences in percentage of deviant dose measurements 
between FB and vmDIBH patients. 
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Limitations 
There are some limitations of the study inherent to its design. First, the number of transit dose 
measurements was limited because radiation fields used for breast cancer are often larger than the 
EPID’s field of view. The limited size of the flat panel portal imagers is an ongoing problem when using 
large treatment volumes. Because of this limited amount of EPID dosimetry data, the study might have 
been underpowered to detect a significant difference among the 3 groups. Second, we verified 2D 
measured transit dose distributions and not the 3-dimensional (3D) delivered dose inside a patient. 
Gamma criteria were deliberately chosen to be larger (5% and 5 mm; in accordance with protocol at 
that time) than usually applied in other publications; in the literature, gamma criteria of 3% and 3 mm 
are often used, but usually for pretreatment verification purposes and for verification of the 3D dose 
inside the patient. Because of changes in breast anatomy and set-up errors, and their large impact on 
the measured transit dose, the broader gamma criteria were chosen to get a better threshold to 
decide whether the expected 3D dose differences would be clinically significant and to balance clinical 
relevance and workload. Although for verification of the 3D delivered dose, 3D EPID dosimetry is 
preferred. Our institute26 showed previously that 2D EPID dosimetry can be used to predict changes 
in dose-volume histogram parameters, indicating that there is a relation between our 2D data and the 
3D delivered dose, at least for this patient group using tangential breast fields for radiation therapy 
treatment. 
 
Conclusion 
Both set-up and 2D EPID dosimetry data indicate that reproducibility of radiation therapy for patients 
treated during FB and vmDIBH is similar. The observed differences in 2D EPID dosimetry were not 
statistically significant between vmDIBH and FB techniques. However, further investigation with 3D 
EPID dosimetry is recommended to investigate the clinical relevance of deviant gamma images. We 
are currently investigating how EPID dosimetry can be used to develop decision rules for adaptive 
radiation therapy. 
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Abstract  
Aim: To investigate whether breast cancer patients’ visits to an outpatient clinic for late outcome 
(OCLO) can be replaced by patient reported outcome measures (PROMs), by comparing late toxicity 
scored at the OCLO with PROMs. 
Methods: All breast cancer patients treated in our institute with adjuvant radiotherapy 10-11 years 
ago were invited to visit the OCLO, and for filling out PROM-questionnaires. Concordance rate 
between PROMs and OCLO-reported outcome and the percentage of patients with ≥ 2 degrees 
difference in toxicity level between patient and clinician was assessed. 
Results:  686 of 1029 patients were still alive.  249 patients visited the OCLO, and 341 patients returned 
a questionnaire. At a group level, patients reported higher toxicity rates than clinicians. The mean 
concordance for individual patients was 58% between patient and clinician reported outcome. In 
2.8%, the clinician reported ≥ 2 degrees higher toxicity than the patients did, whereas in 6.8% patients 
reported ≥ 2 degrees higher toxicity.  
Conclusion: PROMs do not underestimate late side-effects at a group level. In spite of the low 
concordance rate, PROMS can be used to identify patients who experience a heavy burden of side-
effects, requiring specific attention. Therefore, patients can be spared a visit to the OCLO.  
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Introduction   
The oncological outcome of breast cancer patients has improved substantially, resulting in a growing 
number of long-term survivors1. Consequently, the late side effects of treatment and their impact on 
quality of life (QoL) are increasingly important2. There are several reasons to detect and record these 
late side-effects:  
1) to adequately treat the side-effects and assist patients in coping with them 
2) to monitor quality of care and to evaluate the effect of changes in treatment protocols over time  
3) to incorporate information on outcome in the process of shared decision making3.  
The usual way to collect outcome data is through follow-up in outpatient clinics, but due to the 
improved survival these outpatient clinics are expanding rapidly. Therefore, more cost-effective ways 
of follow-up have been investigated, showing that follow-up can safely and satisfyingly be performed 
by general practitioners4 or nurses, or even  by phone5,6. In the Netherlands, in patients older than 60 
years, follow-up from 5 years after treatment (i.e. 2-yearly mammography) is largely performed by 
the general practitioner or via the national screening program in case of mastectomy, according to 
current national guidelines.  Consequently, it is extremely difficult for hospitals to obtain long-term 
outcome data. Since structural outcome registration is an important prerequisite for improving quality 
of care, it would be interesting to know whether questionnaires concerning Patient Reported 
Outcome Measures (PROMs) to score late toxicity can be used instead of a visit to an outpatient clinic. 
Although both the Cambridge Intensity-modulated Radiotherapy (IMRT) Trial7 as well as the START 
trials8 found a low concordance level between late toxicity evaluated by PROMS compared to doctor 
reported toxicity, in the START trials PROMs were found to be sensitive enough to discriminate 
differences in late toxicity between fractionation schedules at 5 years. Data on PROMs more than 5 
years after treatment are still lacking. 
Therefore, we started an outpatient clinic for late outcome (OCLO) at our institute for patients who 
had received adjuvant radiotherapy for breast cancer > 10 years ago to evaluate late side effects.  The 
aim of the current paper is to investigate whether breast cancer patients’ visits to an outpatient clinic 
for late outcome (OCLO) can be replaced by PROMs, by comparing the concordance between late 
toxicity scored at the OCLO with PROMs. For this purpose, we addressed the following questions:  
1) Can PROMs be used to monitor quality of care, or to evaluate a change in treatment? For this, 
concordance between toxicity reported by PROMs and by the clinician on a group level should be 
determined.  
2) Can PROMs be used to identify patients that need special attention for side-effects, i.e. what is 
the concordance at the individual level between toxicity and outcome registered using PROMs 
compared to registered by clinicians?  
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3) How often do we severely underestimate toxicity by using only PROMs?  
4) Can PROMs be used to register oncological outcome, i.e. what is on average the concordance of 
patient reported and real oncological outcome? 
 
Methods 
Patients and inclusion procedures 
The study population consisted of breast cancer patients treated with a curative intent including 
radiotherapy at least 10 years ago, i.e. between 2002 and 2005. Patients treated for recurrent breast 
cancer were excluded. Eligible patients were extracted from the digital hospital information system. 
Survival status was assessed using the population register. Patients alive and whose addresses could 
be retrieved were asked to visit the OCLO and to fill in PROM-questionnaires. They could respond with 
an acceptance to visit the OCLO with or without PROM-questionnaires, or a rejection, with or without 
questionnaires. 
Data regarding tumor and treatment characteristics were retrieved from patient files. 
Patients who visited the OCLO, were seen by a resident in radiation oncology (PB) or a trial physician 
assistant (JP), specifically trained for this purpose. The study protocol was approved by the medical 
ethics committee of the Maastricht University Medical Centre (MUMC+) and registered at 
ClinicalTrials.gov (NCT01978756).  
 
Outcome measures  
Toxicity 
Toxicity was scored both at the OCLO and by using PROM-questionnaires. For late toxicity we focused 
on cosmetic outcome, fibrosis, shoulder function, lymphedema, neuropathy, fatigue and pain. 
At the OCLO, cosmetic outcome was scored on a four-point scale9 by the clinician. Physical 
examination was performed to evaluate fibrosis of the breast using a 4-point scale according to the 
common toxicity criteria version 4.0 (CTCAE v 4.0). Assessment of lymphedema and shoulder mobility 
was performed according to the method applied in the AMAROS trial10: lymphedema assessment 
included recording any sign of lymphedema, and measuring arm circumference of the upper and lower 
arm (15 cm above and below the medial epicondyle, respectively). Regarding shoulder mobility, the 
range of motion in both arms in degrees was measured and compared in six excursions: abduction, 
adduction, anteversion, retroversion, exorotation and endorotation.  
To assess late toxicity in the PROM-questionnaires, we used the validated EORTC- QLQ_C30 
questionnaire for overall quality of life11 and the breast cancer specific BR-2312. For the current paper, 
we only analyzed question 18 of the EORTC- QLQ_C30 questionnaire concerning fatigue, and 
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questions 48, 49 and 50 of the BR-23 concerning lymphedema, shoulder function and pain. For 
cosmetic outcome, the validated questionnaire of Sneeuw et al was used13, containing questions on 
symmetry, firmness and satisfaction. Further, we added some questions on neuropathy to the PROM-
questionnaire, conform the CTCAE v 4.0 score.  All toxicity scores were thus reported on a four-point 
scale, with exception of patient reported satisfaction: this was scored on a five-point scale.  
 
Oncological outcome 
Data regarding locoregional recurrence and distant metastases were retrieved from the medical 
records. 
To assess patient reported disease status, questions on whether the disease had recurred, and if so 
when and where, were included in the questionnaire. 
 
Statistical analysis  
Descriptive statistics were used to describe the study population and to give an overview of the 
measured endpoints. For continuous variables this included the mean, standard deviation and range.  
Secondly, we compared the data from the questionnaires with the data obtained at the OCLO using t-
tests or Chi-square tests, with the data-source (OCLO or questionnaire) being the independent 
variable, and the corresponding outcome as the dependent data. When comparing the cosmetic 
outcome scores of the questionnaires with corresponding items scored on the OCLO, we divided the 
four category answers in two scales. In the questionnaire, cosmetic outcome was scored on a five-
point scale: for this item very satisfied and satisfied were taken together as ‘satisfactory’, and the 
three worst categories (not dissatisfied, dissatisfied and very dissatisfied) were merged together as 
‘not satisfactory’.  
Concerning lymphedema and shoulder function, we compared the treated side with the untreated 
side. In case of a history of bilateral breast carcinoma, patients were removed from the analysis. Both 
shoulder function and lymphedema were converted to a 4-point scale.  
Concerning oncological outcome, patient reported disease recurrence was compared with data from 
the patient files.  Five- and 10-year actuarial survival rates were determined based on the data 
retrieved from the patient files.  
Finally, we determined the percentage of concordance for patients of whom both OCLO data and 
questionnaires were available. For this purpose, we used the full scales. In case of a 5-point scale, two 
categories were taken together to create a logical 4-point scale. For instance, in case of lymphedema, 
a measured arm circumference of less than 95% and a normal arm circumference (95%-105%) were 
pooled together and set equal to “I do not suffer from lymphedema”. We calculated percentage of 
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full agreement, but we also explored the non-concordant cases. To assess whether late toxicity would 
be underestimated using questionnaires only, the number of patients with a toxicity score at the OCLO 
of 2 or more degrees worse than in the questionnaire was assessed. A limit of 5% was regarded as 
acceptable and a one-proportion z-test was performed to test exceeding this limit. 
 
Results 
The study population consisted of 1029 patients who received adjuvant radiotherapy for primary 
breast cancer between 2002 and 2005. Patient files were available for all these patients (Fig. 1 and 
Table 1).  686 of them were alive and invited to visit the OCLO and fill out questionnaires. 249 patients 
(36%) agreed to visit the OCLO of whom 244 also answered the questionnaires. In total, 341 (50%) 
patients filled in the questionnaire (Fig. 1).  
Patient and treatment characteristics are given in Table 1; as indicated by the p-value, the OCLO study 
population differed from patients not visiting the OCLO with respect to age, stage, type of surgery and 
type of treatment.  
 
Figure 1. Overview of data analysed in the outpatient clinic for late outcome (OCLO). The five patients 
who visited the OCLO but did not complete the questionnaire, were excluded from the toxicity analysis 
and analysed in the ‘patient file only’ group.  
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Table 1. Patient and treatment characteristics for the different patient groups.  
 
 
 
 All patients OCLO, 
questionnaire 
and patient 
file 
No OCLO, only 
questionnaire 
and patient 
file 
Only patient 
file 
p-value 
Number of patients 1029 244 97 688  
      
Mean age (SD) 59 (12.2) 54 (8.5) 57 (10.5) 61 (13.0) 0.005 
  
Stage     0.005 
Stage 0 26 (2.5%) 4 (1.6%) 6 (6.2%) 16 (2.3%)  
Stage I 432 (42%) 125 (51.2%) 42 (53.3%) 265 (38.5%)  
Stage II 355 (34.3%) 87 (35.7%) 36 (37.1%) 232 (33.7%)  
Stage III 141 (13.7%) 22 (9.0%) 8 (8.2%) 111 (16.1%)  
Stage IV 2 (0.2%) NA NA 2 (0.3%)  
unknown 73 (7.1%) 6 (2.5%) 5 (5.2%) 62 (9.0%)  
  
Surgery     0.05 
Mastectomy 125 (12.1%) 28 (11.5%) 5 (5.2%) 92 (13.4%)  
Breast conserving surgery 887 (86.2%) 213 (87.3%) 92 (94.8%) 582 (84.6%)  
Unknown 17 (1.7%) 3 (1.2%) NA 14 (2.0%)  
  
Systemic treatment  
(chemotherapy) 
    0.26 
Chemotherapy 443 (43.1%) 118 (48.4%) 40 (41.2%) 285 (41.4%)  
No chemotherapy 557 (54.1%) 124 (50.8%) 57 (58.8%) 376 (54.7%)  
unknown 29 (2.8%) 2 (0.8%) NA 27 (3.9%)  
  
Systemic treatment 
(endocrine therapy) 
    0.10 
Endocrine therapy 389 (37.8%) 106 (43.3%) 31 (32.0%) 252 (36.6%)  
No endocrine therapy 595 (57.8%) 132 (54.1%) 65 (67.0%) 398 (57.8%)  
Unknown 45 (4.4%) 6 (2.5%) 1 (1.0%) 38 (5.5%)  
  
Treatment:      0.002 
Only surgery and 
radiotherapy 
434 (42.2%) 105 (43.0%) 49 (50.5%) 280 (40.7%)  
Surgery, radiotherapy and 
chemotherapy 
160 (15.5%) 27 (11.1%) 16 (16.5%) 117 (17.0%)  
Surgery, radiotherapy and 
endocrine therapy 
113 (11.0%) 18 (7.4%) 8 (8.2%) 87 (12.6%)  
Surgery, radiotherapy, 
chemotherapy and 
endocrine therapy 
275 (26.7%) 88 (36.1%) 23 (23.7%) 164 (23.8%)  
Unknown 47 (4.6%) 6 (2.5%) 1 (1.0%) 40 (5.8%)  
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Toxicity scored by clinicians at the OCLO and by patients in the PROM-questionnaire (presented in all 
patients returning the PROM-questionnaire and only the patients visiting the OCLO) are shown in 
Table 2.  The patient reported incidence of all side-effects except any pain was at a group level higher 
than reported at the OCLO with differences in incidence varying from 2% for severe pain, to 19% for 
fatigue or any lymphedema (Table 2 and Figure 2).   
At an individual level, the average concordance rate in toxicity scores between PROMs and the OCLO 
was 60% (Table 3). The agreement was lowest for fibrosis (40.5%) and cosmetic outcome (46.6%), and 
the highest for edema, shoulder function and neuropathy (63.7-67.5%).  
Concerning the patients with non-concordant scores, 26.3% (17.8%-39.5%) of the patients reported 
higher levels of toxicity than the clinician did, whereas in 13.3% (7.1%-20.0%) the clinician at the OCLO 
reported higher levels. For example, cosmetic outcome was scored worse by the clinician than by the 
PROMs questionnaire in 19.1%, while in 34.4% the patient reported worse outcome than scored at 
the OCLO (Table 3). 
In 6.7% patients reported a ≥ 2 degrees higher toxicity than scored at the OCLO, and in 2.1% clinicians 
reported a ≥ 2 degrees worse toxicity at the OCLO than patients in the questionnaire. For all toxicities, 
< 5% of patients underestimated their toxicity with ≥ 2 degrees compared to the clinician. However, 
statistical analysis showed that we could not exclude that the population percentage with 
underestimation of their toxicity with ≥ 2 degrees was larger than 5%, for fibrosis, shoulder function, 
lymphedema (lower arm) and motor neuropathy.  
With respect to oncological outcome, we found that of the 1029 patients, 686 patients (67%) were 
still alive at about 10 years after treatment. 5- and 10-year actuarial overall survival (OS) were 84.6% 
and 67.9% respectively (Table 4).  Locoregional control at 10 years was 91.8% for all patients. Patients 
visiting the OCLO had a better locoregional control than patients who did not (97.5% vs 88.1% 
p<0.001). The same was observed for disease free survival (DFS): 10 year DFS for all patients was 
72.5%, and 93.9% for the OCLO group compared to 60.2% (p<0.001) for patients who did not visit the 
OCLO (Table 4).  
Regarding concordance in oncological outcome, 21 patients had a recurrence based on data of the 
OCLO and patient files. In two of these patients, disease recurrence was not mentioned in the 
questionnaire. In 9 cases, patients reported disease recurrence while patient files did not (3%). Of 
these 9 patients, 6 patients had developed a second primary tumor, either in the ipsilateral breast (N 
= 1 different histology), the contralateral breast (N = 3), or elsewhere (N = 2).  Due to low number of 
events significance levels could not be assessed.    
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Outcome recorded by 
clinician at the  OCLO 
(N =244 ) 
Outcome recorded by 
patients using 
questionnaires, and 
also visiting the OCLO 
(N = 244) 
Outcome recorded by 
all patients using 
questionnaires  
(N = 341) 
 N / total % N / total % N / total % 
Satisfied cosmetic 
outcome 
124/202 61% 107/189  57% 168/282 60% 
Fibrosis whole breast 
severe 
5/211 2% 21/195  11% 28/278 10% 
Fibrosis whole breast 
moderate / severe 
44/211  21% 66/195  34% 85/283 30% 
Pain in breast area  
any 
120/243 49% 110/236  47% 137/332 41% 
Pain in breast area 
more than a little 
24/243  10% 33/236 14% 41/332 12% 
Pain in breast area 
severe 
3/243 1% 7/236 3% 9/332 3% 
Lymphedema  
any 
20/165  12% 49/156  31% 98/324 30% 
Impaired shoulder 
function * 
18-50 
/220  
8-22% 68/214  32% 111/332 33% 
Neuropathy-sensory 
Any sign 
73/243  30% 95/229  41% 135/323 42% 
Neuropathy-sensory 
Impaired function 
19/243  8% 44/229  19% 57/323 18% 
Neuropathy-motor 
Any sign 
66/243  27% 88/234  38% 125/331 38% 
Neuropathy-motor 
Impaired function 
37/243  15% 49/234  21% 72/331 22% 
Fatigue   
any 
112/243  46% 153/237  65% 220/333 66% 
Fatigue  
more than a little 
48/243  20% 93/237 25% 80/333 24% 
       
Table 2. Toxicity scored by patient at the questionnaire and measured or asked at the outpatient clinic 
for late outcome (OCLO). Patients who underwent a mastectomy did not report on fibrosis and 
cosmetic outcome. * Shoulder function was distracted from six different shoulder excursions, 
therefore we only mentioned the lowest and the highest incidence of the six measures of impaired 
shoulder function. 
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Figure 2. Comparison between patient questionnaire and clinician assessment of late toxicity at 10 
years of patients visited the outpatient clinic of late outcome (OCLO). The data are limited to those 
patients of whom both the score at the OCLO and on the questionnaire were available. 
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n = 234
questionnaire
OCLO
58.5%
22.3%
14.4%
4.8%
70.3%
21.4%
6.6%
1.7%
normal grade 1 grade 2 grade 3
Neuropathy sensory
n = 229
questionnaire
OCLO
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N OCLO = Q OCLO > Q OCLO < Q 
OCLO > Q 
(≥ 2) 
OCLO < Q 
(≤ 2) 
p-value* 
Cosmetic  
outcome 
189 46.6% 19.1% 34.4% 1.6% 3.2% 0.03 
Fibrosis (whole 
breast) 
195 40.5% 20.0% 39.5% 4.1% 12.3% 0.56 
Pain in irradiated 
area 
236 65.7% 16.5% 17.8% 1.3% 3.0% <0.01 
Shoulder function 
(abduction) 
214 65.9% 14.5% 19.6% 4.7% 4.7% 0.84 
Shoulder function 
(anteversion) 
214 65.9% 12.6% 21.5% 2.8% 5.1% 0.14 
Lymphedema 
(Upper arm) 
156 66.7% 7.1% 26.3% 0.0% 8.9% 0.004 
Lymphedema 
(Lower arm) 
155 63.9% 12.3% 23.9% 2.6% 9.7% 0.17 
Neuropathy 
(sensory) 
229 63.7% 9.6% 26.6% 0.9% 8.3% 0.004 
Neuropathy 
(motor) 
234 67.5% 10.7% 21.8% 3.0% 9.4% 0.16 
Fatigue 237 57.8% 10.5% 31.6% 0.0% 2.5% <0.001 
Mean  60.4% 13.3% 26.3% 2.1% 6.7%  
        
Table 3. Concordance of toxicity reported at the outpatient clinic for late outcome (OCLO) and 
reported in the questionnaire (Q). 
OCLO = Q means a full agreement between the grade of toxicity scored at the OCLO by the 
physician/trial nurse and the grade of toxicity reported by the patient in the questionnaire.  
OCLO > Q means that at the OCLO higher grades of toxicity were scored by the physician/trial nurse 
than patients reported in the questionnaire. In case of OCLO < Q, patients reported higher levels of 
toxicity in the questionnaire than scored at the OCLO.  
(≥ 2) levels implies that the difference is at least 2 degrees (for instance, patient reports excellent 
cosmesis, but at the OCLO moderate or poor cosmetic outcome is scored).  
In the marked row the difference is at least 2 degrees worse reported at the OCLO as reported in the 
questionnaire.  
*p-value from z-test for a single proportion with null hypothesis value of 5% calculated for OCLO > Q 
(≥ 2). P-values > 0.05 mean that the null-hypothesis, that the population percentage is > 5%, cannot 
be rejected. 
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 N  
N (missing) 
5-year (95% CI) 10-year (95% CI) 
p-
value 
Overall survival 
 
All patients 1026 (3) 84.6 (82.4-86.8) 67.9 (65.0-70.8)  
Only patient file 685 (3) 76.6 (73.4-79.8) 49.3 (45.1-53.5)  
Locoregional recurrence free survival 
 
All patients 823 (206) 95.9 (94.5-97.3) 91.8 (89.6-94.0)  
Visited OCLO 244 (0) 98.8 (97.4-100.0) 97.5 (95.5-99.5) 
<0.001 
Not visited OCLO 579 (206) 94.6 (92.6-96.6) 88.1 (85.2-91.4) 
Questionnaire 
(OCLO and no OCLO) 
341 (0) 97.9 (96.3-99.5) 95.6 (93.4-97.8) 
 
Disease free survival 
 
All patients 924 (105) 83.9 (81.3-86.5) 72.1 (68.7-75.5)  
Visited OCLO 244 (0) 97.5 (95.5-99.5) 93.9 (90.9-96.9) 
<0.001 
Not visited OCLO 680 (105) 78.4 (75.1-81.7) 60.2 (55.5-64.9) 
Reported by patients 
visited OCLO 
228 (16) 95.6 (92.8-98.4) 91.2 (87.4-95.0) 
 
Questionnaire 
(OCLO and no OCLO) 
341 (0) 97.0 (95.2-98.8) 92.0 (88.8-95.2) 
 
 
Table 4. Overall survival, locoregional recurrence free survival, metastasis free survival and disease 
free survival for the separate groups. Overall survival for the OCLO/questionnaire group is not 
shown, as it is 100%.  
 
Discussion 
We showed that, at a group level, PROMs do not underestimate late toxicity, such that they can safely 
be used to monitor quality of care or changes of treatment protocols. In addition, we found that when 
looking at individual scores, questionnaires and OCLO were non-concordant in 40%: in 13% side effects 
were scored more severe at the OCLO, and in 26% the side effects were scored more severe when 
using the questionnaires. This may raise the question whether PROMs can be used to identify patients 
who need special attention for late toxicity. Although < 5% of patients underestimated their toxicity 
with ≥ 2 degrees compared to the clinician, statistical analysis showed that for fibrosis, shoulder 
function, lymphedema (lower arm) and motor neuropathy this threshold may be exceeded. Finally, 
we found only a low number of recurrences in the questionnaire population, such that no firm 
conclusions can be drawn on the use of PROMs to assess oncological outcome. 
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Interpretation of the results and comparison with literature 
In our study, the toxicity measured at a group level using PROMs was somewhat higher than reported 
by the clinician at the OCLO, which corresponds to the data of the START trial, where also somewhat 
higher levels of toxicity were found in the PROMs. The same was observed in the PORTEC-3 trial for 
endometrial carcinoma14. In contrast, in the Cambridge Breast Intensity-modulated Radiotherapy 
trial7 physicians scored higher rates of late toxicity than the patients did, which they ascribed to 
adaptation of patients to their health situation.  This might also explain the possibility of missing 
severe toxicity in case of fibrosis, shoulder function, lymphedema (lower arm) and neuropathy (motor) 
in this study. 
With respect to comparing the data at an individual level, our concordance rates are in line with other 
studies where PROMs are compared with doctor-reported outcome data after radiotherapy for breast 
cancer. Both the START trials8 and the Cambridge Breast Intensity-modulated Radiotherapy (IMRT) 
trial7 showed levels of agreement between 39% and 86% at 5 years,  comparable to our findings at ten 
years (41-67%). 
Since the agreement between PROMs and physician reported outcome is generally low, the question 
arises which reported outcome is ‘true’ or most useful. Whether PROMs are sufficiently reliable 
depends on the purpose of outcome registration: A) When toxicity is registered with the objective to 
identify patients who need extra attention, we need a tool that defines the burden of toxicity to 
patient, for which PROMs are very suitable7,15, such that we conclude that we can use PROMs for this 
purpose, in spite of the low concordance rate; B) When outcome registration is used to monitor quality 
of care, and changes in treatment protocols, the START trials8 showed that PROMs are sensitive 
enough to detect differences. However, since we found that fibrosis, shoulder function, lymphedema 
(lower arm) and motor neuropathy may be underestimated with ≥ 2 degrees in > 5% of the population, 
we need to interpret the data for this purpose with some caution; C) When outcome registration is 
however used to identify clues on how to improve outcome, more objective outcome registration 
might be needed. For cosmetic outcome for instance, digital photographs can be used for that 
purpose16. 
With respect to oncological outcome, we can only compare the locoregional recurrence rate with 
literature, since we are not aware of data presenting OS and DFS of patients selected by the fact that 
they were treated with adjuvant radiotherapy.  We found a locoregional recurrence rate of less than 
1% per year, which is comparable with literature regarding the same period of time17.  Two of 21 
patients with recurrent disease would have been missed if questionnaires only had been used, and 
nine patients reported a ‘false’ disease recurrence. This latter finding is considered less problematic, 
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since a reported recurrence can actively be verified. However, due to the low response rate, we cannot 
rely on questionnaires only to assess oncological outcome. 
 
Study limitations 
A limitation of this study is the relatively low number of patients that was willing to visit the OCLO 
(249/686 = 36%) and to fill out the questionnaires (341/686 = 50%), which could raise questions on 
the representativeness of the study population of responding patients.  
The oncological outcome of patients visiting the OCLO or filling out questionnaires was better than 
patients not responding at all, suggesting that disease free patients were more inclined to respond 
than patients with a recurrence.   
Obviously, patients filling in the questionnaire or visiting the OCLO, were not representative for the 
whole patient population regarding (locoregional) survival.  The same holds probably true for the 
absolute incidence of toxicity. Since the percentage of patients willing to visit the OCLO was low, we 
added the possibility to fill in why they were not willing to come to the OCLO. The main reasons were 
the absence of complaints, followed by a too far travel distance. However, it cannot be excluded that 
for patients who did not respond at all, toxicity could be worse or better.   
Nevertheless, despite possibly doubtful representativeness of our patient population, one can assume 
that the concordance between PROMs and late toxicity scored by the clinician would be the same for 
patients not visiting the OCLO.  Consequently, although we have to be cautious to interpret the results 
with respect to the absolute toxicity levels, we consider the analyses of concordance levels reliable. 
Another limitation is the fact that we do not have baseline PROMs but only have PROM-data at 10-
year follow up. Therefore, changes over time cannot be described.   
 
Consequences for clinical practice 
Our institute recently started using PROMs on a regular base, beginning before the start of 
radiotherapy to determine a baseline score. Subsequently, patients receive a questionnaire 3 weeks 
and 3, 6 and 12 months after treatment, and thereafter yearly until at least 10 years after treatment18 
(see supplementary file). Acute toxicity is also scored by the physician according to CTCAE v4.0 before, 
during and until 4-6 weeks after treatment.  PROMs are screened by an employee to identify toxicity 
scores ≥ grade 3, which are then immediately reported to the treating radiation oncologist for 
evaluation, who, if needed, undertakes action. The PROMs also contain validated utility and quality of 
life questionnaires, such as EQ5D, QLQ-C30 and tumor specific EORTC modules in accordance with the 
ICHOM outcome sets19, to facilitate benchmarking in the future. For this purpose, data on treatment 
and patient variables, including comorbidity, are systematically collected as well. 
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Conclusion 
The current study shows that patients are more willing to return a questionnaire than visiting the 
OCLO and provides us sufficient information that one can rely on PROMs for the recording of late side-
effects on a group level, and for identifying patients who need attention because of severe complaints. 
Therefore, by using PROMs, the patient can be saved a visit to the hospital. 
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General discussion  
A growing number of breast cancer patients can be cured and consequently patients live longer after 
treatment1,2. Therefore, it is important to have knowledge about the severity and incidence of various 
late side effects of treatment and their severity. This knowledge is not only required to find clues for 
mitigation late side effects, the information is also required for shared decision making (SDM) on 
choosing for radiotherapy yes or no. 
In this thesis we mainly focussed on the cosmetic analysis of the Young Boost Trial (YBT). We 
determined which factors are important for patient reported cosmetic outcome, fibrosis and cosmetic 
outcome. Further, we report on an easy but reproducible and affordable breath hold manoeuvre to 
reduce the dose to the heart (Voluntary moderately Deep Inspiration Breath Hold, vmDIBH), to 
mitigate radiation-induced cardiac injury. At last we investigated whether patient reported outcome 
measures (PROMS) are sufficiently reliable to record late outcome. 
 
Cosmesis 
Previous studies showed increased fibrosis3 and decreased cosmetic outcome4 following breast 
radiation therapy. In the YBT only 63% of patients who received a 16 Gy boost found their cosmetic 
outcome satisfactory. This number decreases to 53% in case a 26 Gy boost was given5.   We were able 
to define the distance from nipple to inframammary fold and the length of the breast contour as the 
most important symmetry features for a patient to like her aesthetic outcome6. Additionally, the 
chance for a patient to dislike the cosmetic outcome increases with increasing severity of fibrosis6.  
Further, in our analysis, a 26 Gy boost dose compared to a 16 Gy boost dose, poor cosmesis before 
start radiation treatment (baseline cosmesis), a photon boost instead of an electron boost, a large 
boost volume and adjuvant chemotherapy were defined as risk factors for worse cosmetic outcome5.  
From the literature many other risk factors for cosmetic outcome are known such as smoking7, dose 
homogeneity8, breast size7,9, supine instead of prone position10, total dose (hypofractionation)11,12, 
dose max13–15, excision volume16,17, tumour size16, re-excision18, oncoplastic surgery19, location of the 
tumour4,9,16 and postoperative complications7,9. Some of these factors cannot be influenced, for 
example breast size or tumour location. In some cases, there is a strong indication for chemotherapy. 
On the other hand, other (radiation associated) factors as dose homogeneity, maximum dose, and 
total dose (use of hypofractionation) and perhaps boost volume and/or boost dose might be 
influenced. However, despite the fact we know more about potential risk factors, there is still a lack 
of knowledge how to deal with them. For instance, it is unknown what we should consider as the 
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optimal radiation plan. Is it better to plan the boost dose with the tangential fields to lower the dose 
in the heart and lungs, or is an extra beam or arc preferred to deliver the boost dose with the 
consequence a slightly higher dose into the heart and/or lungs? Except in extreme cases, there is no 
single best answer to these questions. The answer is a balance between the probability and severity 
of avoidable side effects, the chance for achieving tumour control and the preferences of the patient. 
Further, the use of oncoplastic surgery is increasingly becoming part of routine breast cancer surgical 
management20,21. Although  the aim of oncoplastic surgery is to improve aesthetic outcome without 
compromising oncological safety21, for now there are no publications showing that oncoplastic surgery 
is actually leading to a better cosmetic outcome20,22. Lansu et al analysed a subgroup of the YBT (single 
centre) and found that patients who underwent oncoplastic surgery scored even a significantly worse 
cosmetic outcome, based on the objective BCCT.core tool19. However, this analysis was performed 
after only one year follow up. A possible explanation for this worse cosmetic outcome could be that 
the gain in cosmetic outcome achieved by oncoplastic surgery is counterbalanced by the radiation 
treatment. Oncoplastic surgery might result in larger amount of seroma, although there is no literature 
to support or disprove this hypothesis. Furthermore, tumour bed delineation for radiotherapy will be 
more difficult due to large mammary gland translations, rotations or excisions, which could lead to 
larger boost volumes. Boost volume is, as we showed, an important risk factor for worse cosmetic 
outcome. Unfortunately, no results of randomized controlled trials, comparing oncoplastic surgery 
with standard lumpectomy, are yet available. The same is true for long term results after oncoplastic 
surgery. For now, the question remains whether or not a patient benefits from oncoplastic surgery.  
 
Prevention of heart toxicity 
In the Netherlands, an estimated number of 752.400 women suffered with cardiovascular disease, 
corresponding to 87 per 1000 women23. Radiotherapy for breast cancer, i.e. exposure of the heart to 
ionizing radiation, increases the risk of coronary heart disease as well as cardiac mortality24 with a 
proportional  increased rate of major coronary events by 7.4% per Gray mean heart dose25. Therefore, 
it is of great importance to keep the heart dose as low as possible. We showed a reproducible and 
affordable breath hold maneuver to reduce the dose to the heart26. This technique has been verified 
in the UK Heart study27,28. More controlled alternatives for voluntary breath hold are both active 
breathing control (ABC), using a spirometry-based device, and gating29, a non-invasive, video-based 
system using a lightweight device placed at the surface of the patient.  
All previous techniques are based on the breath hold technique, in which the heart moves away 
from the tangential fields. Mast et al performed a planning study and showed that with proton 
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therapy dose to the heart could be reduced in the majority of the cases to almost zero, even without 
a breath hold30. In the Netherlands, proton therapy became just recently available, but the health 
insurer only reimburses treatment in selected cases. A patient is eligible to receive proton therapy in 
case of a clinically relevant difference in the probability to develop a certain complication between 
proton and photon therapy. For breast cancer, cardiac injury is for now the only endpoint included in 
the national indication protocol for proton therapy.  The risk on acute coronary events (ACE) is 
estimated based on the Darby model, where the relative risk of developing ACE is applied to the 
Dutch incidence of ACE, resulting in a table where the risk on ACE can be estimated based on 
gender, age, presence of cardiovascular risk factors, and the mean heart dose25. MacDonald et al. 
showed that the average mean heart dose (MHD) could be limited to 0.44 Gy (range, 0.1-1.2 Gy) in 
patients with left sided breast cancer, treated with proton therapy31, compared to reported mean 
heart doses of 2.9 ± 1.5 Gy in photon therapy planning32. Proton therapy can thus reduce the dose 
to the heart and will be most appropriate for women with underlying cardiopulmonary risk factors, 
unfavorable chest anatomy, medial or inferior breast tumors, or in case of radiation of the internal 
mammary nodes31. 
However, as mentioned above, no consensus concerning the optimal radiation plan exists. One 
might wonder if, in selected cases, a concession to the medial part of the target volume, resulting in 
a lower heart dose, might be acceptable, and thereby a more efficient way to spare the heart than 
proton therapy. Unfortunately, no outcome data concerning these concessions of the target volume 
exist, such that up till now it seems more reasonable to strive for optimal target coverage   
In the Netherlands, cancer is the most common cause of death for women, followed by cardiovascular 
disease33. Women with breast cancer have a higher risk of mortality caused by cardiovascular disease 
than women from the general population34. These higher mortality rates can partly be explained by 
treatment effects, both systemic treatment since anthracycline-based chemotherapy, 
trastuzumab35,36 and radiation treatment24 have been reported to increase the risk of cardiovascular 
disease. Cheng et al. performed a literature review and reported an absolute risk increase of 76.4 
cases of coronary heart disease and 125.5 cases of cardiac death per 100.000 person-years24. 
However, one must also be aware of the shared risk factors for cancer and cardiovascular disease. 
Smoking, obesity, poor diet, and physical inactivity can cause both heart disease and cancer37. For 
example, a sedentary woman who introduces the recommended 150 minutes of weekly activity can 
reduce her breast cancer risk by 6%37;  physical activity reduces cancer mortality with 1%  for each 15-
minute increase in daily physical activity37.  Consequently, patients at risk for cardiac morbidity and 
mortality should be identified and encouraged to adjust their lifestyle and quit smoking, lose weight 
if necessary and adopt physical exercise in their daily life.  
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To optimize treatment related side effects, identification of patients with a high risk of cardiac 
morbidity and mortality is important. The question is whether it is useful to screen for cardiac disease 
during follow up and, in case of screening, how to screen, and for exactly which cardiac disease. 
Radiation treatment of thoracic malignancies, for example breast cancer,  can cause several types of 
cardiac injury, such as pericardial disease, ischemic heart disease, valvular disease, conduction system 
disease, autonomic changes, and cardiomyopathy38. The exact pathophysiology of radiation induced 
cardiovascular disease is still unclear, but one assumption is that radiation induced microvascular 
ischemia can lead to disruption of capillary endothelial framework, and injury to differentiated 
myocytes results in deposition of collagen and fibrosis. In the presence of risk factors of a metabolic 
syndrome and preexisting atherosclerosis, exposure of the heart to radiation results in accelerated 
occurrence of major coronary events39.  In patients who develop coronary stenosis,  the left anterior 
descending coronary artery (LAD) is involved in 85% of patients, and in 62% it was the sole vessel 
affected40. One might assume it can be useful to be able to identify the healthy woman with a single 
affected coronary artery stenosis, to be able to treat them before a myocardial infarction occurs.  
Investigators from MD Anderson Cancer Center made an algorithm for follow-up in irradiated patients 
with thoracic malignancies39. At baseline risk factors for cardiovascular disease are assessed and based 
on the risk stratification, follow up with echocardiogram is recommended to start 6 months after 
cardiotoxic chemotherapy and/or radiotherapy, to be continued during five or 10 years follow up, 
dependent of the risk profile. Assessment of biomarkers for cardiac damage is promising but still 
experimental39.   
 
The importance of scoring toxicity for shared decision making (SDM) 
In the current society, SDM is becoming increasingly important. In the latest accreditation program of 
the NIAZ (Netherlands Institute for Healthcare Accreditation), Qmentum Global, which will be used 
from 2020, patient and family oriented care is leading in all aspects of healthcare planning, provision 
and evaluation41. Consequently, patients need to be informed about the aim of radiation treatment 
and possible side effects, when choosing between breast conserving surgery or a mastectomy. Also, 
in case of breast conserving surgery, patients may want to participate in the choice of whether or not 
receiving a boost. To help a patient with her decision, a predictive model for cosmetic outcome would 
be very helpful.  
Besides cosmetic outcome and the above mentioned heart damage, other late side effect as 
secondary cancers, limited shoulder movement, pain in the breast or ribs or oedema of the breast or 
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arm can occur. However, not much is known about the exact risk factors and the contribution of these 
individual risk factors to the final actual risk for late toxicity and prediction models are still absent. 
Further, when using modern radiation techniques as intensity-modulated radiotherapy (IMRT) or 
volumetric-modulated arc therapy (VMAT), distribution in organs at risk will be different42. Long term 
follow up data of these new radiation techniques are missing.  
Therefore, we believe it is important to score late side effects in a structural way. This allows us to 
gain knowledge about the possible side effects and their severity in our own patient population. Our 
study showed that one can rely on PROMs for the recording of late side-effects and for identifying 
patients who need attention because of severe complaints43. Our institute recently started using 
PROMs on a regular base, enabling collection of valuable data regarding late side effects of our own 
patient population, which can be used in the SDM discussion with the patient.    
 
Future perspectives 
As described above, there are still many uncertainties concerning the long term effect of oncoplastic 
surgery on cosmetic outcome and the optimal radiotherapy planning. Various initiatives have now 
been taken to collect data on the result of oncoplastic surgery. For example, in the TOBO trial the 
Breast-Q questionnaire is used to investigate the patients' satisfaction concerning her breast after 
oncoplastic breast reconstruction and will be compared with the satisfaction of patients that receive 
a breast conserving surgery without reconstruction44.  
Further, in the Netherlands, a project has started to reach national consensus on plan evaluation 
criteria. Four benchmark cases (breast, breast with boost, breast with axilla level I-IV and breast with 
axilla I-IV including internal mammary lymph nodes) have spread out among the various Dutch 
radiation treatment institutions to be delineated and planned. Results will be analysed and discussed 
to reach consensus and thereby improve dose planning at national level. 
In healthcare, the number of quality indicators have been growing in the last years, with an ever-
increasing administrative burden as a result. Quality indicators are measurable aspects of the 
provision of care, which provide an indication of the degree of quality45. Further, the government, 
health insurance companies and patient organizations call for more transparency regarding these 
quality indicators. The Dutch Organization for Radiation Oncology (NVRO) has worked out a number 
of specific indicators for radiotherapy, including indicators regarding outcome. Examples of outcome 
indicators include tumor control, side effects, quality of life and patient satisfaction and scoring these 
items is becoming to be obligatory. The goal is that radiotherapy departments compare (benchmark) 
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their score on the indicators with other radiotherapy departments. Departments that perform below 
average will be highly motivated to improve. Besides, the best performing departments can be asked 
to share their best practice with the other departments to allow the remaining departments to catch 
up faster46. 
 
Conclusion 
We studied several aspects of late side effects. We found that the use of a photon boost instead of an 
electron boost, a high boost dose (26 Gy compared to 16 Gy), cosmesis at baseline, adjuvant 
chemotherapy and boost volume have an adverse impact om cosmetic outcome. The next step will be 
to develop a nomogram to estimate cosmetic outcome, to use in shared decision making on radiation 
treatment.  
In addition, we found that our technique of vmDIBH is as reproducible as radiation therapy during free 
breathing, making it an easy and valuable tool to reduce irradiate heart volume and thereby late 
cardiac injury. Currently proton therapy is implemented in the Netherlands to further reduce cardiac 
injury in selected patients. 
Finally, we showed that scoring of late side-effects by patient questionnaires is a meaningful way to 
record late side-effects in a structured manner. It does not only enable identifying patients who need 
additional care, but it will also allow to analyse data at a group level, e.g. to analyse time-trends within 
the institute and differences between institutes  
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Summary 
 
Breast cancer 
Chapter 1 provides an introduction to the treatment of early stage breast cancer and the side effects 
of radiation therapy, resulting in the questions in this thesis. Breast cancer is the most common cancer 
in women and the risk of being diagnosed with invasive breast cancer has increased over the past 
decades: in the Netherlands, one of seven women will be diagnosed with invasive breast cancer at 
one point in her life. At the same time, breast cancer treatment has improved significantly, almost 
80% of all women diagnosed with breast cancer survives for at least 10 years. Consequently, there is 
an increasing group of long-time survivors. Given the good prognosis of (especially early discovered) 
breast cancer, there is growing attention for limiting the side effects of treatment, and thereby 
improving quality of life as much as possible, whilst maintaining the good oncological outcome.  
Apart from surgery and systemic treatment, radiotherapy plays a major role in the treatment of breast 
cancer. In patients with early breast cancer, breast conserving therapy, i.e. lumpectomy followed by 
breast irradiation, is nowadays considered as standard of care. Optionally, chemotherapy or hormone 
therapy can be added. Adjuvant radiotherapy shows a relative reduction in loco-regional recurrences 
of 60-70% in patients treated with breast conserving surgery. If indicated, an additional dose can be 
given to the original tumour area (the boost).  An additional boost to the tumour bed reduces the risk 
for local failure even further by a factor of 2. By combining surgery with radiation during breast-
conserving treatment, this treatment is at least as safe as the standard mastectomy performed 
decades ago, but with the advantage that women can retain their breasts. 
 
Side effects 
Unfortunately, every anti-cancer treatment also has side effects. In the case of radiation, healthy cells 
can also be damaged. In case of breast conserving therapy, the breast radiation follows after surgery. 
Basically, no visible cancer cells are present anymore, the radiation therapy is a preventive treatment 
to eliminate any microscopic cancer cells and thereby prevent the disease from recur at a later stage. 
Because the exact location of these invisible cancer cell is unknown, we irradiate the whole breast (or 
partial) with or without a boost and whether or not supplemented with elective regional nodal areas. 
Any late side effects that could occur as a result of the radiation are reduced shoulder function, fluid 
retention in the arms (lymphedema, in case of irradiation of the armpit glands) and fibrosis (scarring 
/ hardening) of the breast. The risk of fibrosis and the severity of this fibrosis enlarges with increasing 
radiation dose. Because breast irradiation is administered with tangential fields, there is also a small 
risk of damage to the lungs and in the case of left-sided breast cancer, to the heart. 
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The central theme of these thesis was to get insight in several aspects of some late side effects: 
- To predict cosmetic outcome, not only to have clues how to improve cosmetic outcome, but 
also to use in shared decision making when choosing on radiation treatment. For this purpose, 
we used the data of the Young Boost Trial (YBT). In this trial the effect of a higher boost dose 
on local recurrence and cosmetic outcome was investigated in patients ≤ 50 years of age. We 
analysed the cosmetic outcome of the Young Boost Trial.  
- To prevent late side-effects, i.e. cardiac injury, by investigating whether our technique of 
Voluntary moderately Deep Inspiration Breath Hold (vmDIBH) is actually reproducible. 
- To record all late-side effects in a structured way: 
o to identify patients needing additional care 
o to enable development of prognostic models 
o to be able to compare outcome data with other radiation therapy centres or with 
historic controls.  
 
Consequently, the three main aims of this thesis were:  
1. To determine which factors are important for:  
a. patient reported cosmetic outcome 
b. fibrosis (scored by physician) 
c. cosmetic outcome (based on BCCT.core) 
To determine these factors, we analysed which risk factors were associated with a worse cosmetic 
outcome in the YBT trial, based on the objective BCCT.core score. Further, we reported on the 
amount of moderate/severe fibrosis and defined the risk factors for moderate/severe fibrosis in 
the boost area (Chapters 2 & 3). 
 
2. To investigate/develop an easy but reproducible and affordable breath hold manoeuvre to reduce 
the dose to the heart (Voluntary moderately Deep Inspiration Breath Hold, vmDIBH). 
Chapter 4 reports on the careful step-by-step introduction of voluntary moderately deep 
inspiration breath hold (vmDIBH) in our institute.  
 
3. To investigate whether patient reported outcome measures (PROMS) are sufficiently reliable to 
record late outcome (Chapter 5). 
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Cosmetic outcome and fibrosis 
The EORTC '' boost versus no boost '' study had previously shown that the risk of a local recurrence 
can be reduced further by adding a boost to the whole breast irradiation, compared to irradiation of 
the whole breast alone. However, this study also showed that the younger patients still remained at 
a risk of a local failure of 13.5% percent at ten years. Because this was considered as an unacceptable 
high risk, a new study was designed, the so-called Young Boost Trial (YBT). In this study patients of 50 
years and younger with early breast cancer were randomized between a standard boost dose or a high 
boost dose in addition to whole breast irradiation. The results regarding the influence on the boost 
dose on the risk of a local recurrence are not yet sufficiently mature for analysis, but preliminarily 
results of both arms together show that the risk of a local recurrence is much lower than previously 
estimated (about 2.2% at 4 years).  
 
In chapters 2 and 3 of this thesis we used data from the YBT to analyse cosmetic outcome at 4 years 
of follow up. Defining cosmetic outcome is often considered as controversial, because of its subjective 
nature.  After all, who decides what is "beautiful"? To score cosmetic outcome as objectively as 
possible, we have used the BCCT.core program. This is a software program with which digital 
photographs, can be analysed, resulting in an objective score for the overall cosmetic outcome: 
excellent, good, fair or poor. This score is based on symmetry (7 features), skin colour and scar 
visibility.  
  
Although an objective measure for cosmetic outcome is obviously important, especially in the context 
of studies, or to be able to detect changes over time, patients’ satisfaction regarding her own breast 
is also essential. In chapter 2 we investigated which symmetry features are most important for 
patients to be satisfied with the appearance of her breast. Our analysis showed that the distance 
between the nipple and the inframammary fold (the lower edge of the breast), the length of the breast 
contour and the severity of fibrosis are the most determining factors for patient satisfaction. 
 
In chapter 3 we investigated which treatment-related factors influence cosmetic outcome, based on 
the objective BCCT.core. It turned out that a higher boost dose compared to the standard boost dose, 
a photon boost instead of an electron boost, poor cosmesis before start radiation treatment (baseline 
cosmesis), a large boost volume and adjuvant chemotherapy were defined as risk factors for worse 
cosmetic outcome.  
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Prevention of cardiac toxicity 
Breast or thoracic wall irradiation is generally largely given using tangential fields. In case of left-sided 
breast cancer, the heart can be partially located within the radiation field. It is known that dose to the 
heart can lead to heart damage, whereby the higher the dose in the heart, the higher the risk of heart 
disease during follow up. Therefore, it is important to keep the dose in the heart as low as possible. 
Multiple respiratory techniques have been described to spare the heart. All techniques are based on 
the principle that during deep inspiration the heart moves out of the radiation field. A simple and 
inexpensive method is based on a voluntary breath hold. However, since the breath hold is voluntary, 
it is difficult to properly control this breath hold and therefore the reproducibility of this method is 
questioned. 
 
In chapter 4 we report on the step-by-step implementation of this voluntary moderate deep 
inspiration breath hold (vmDIBH) in Maastro and how we have simplified the technique during the 
implementation process. Initially, patients received 3 CT scans in 2 days. On day 1, two CT-scans were 
obtained; one in both free breathing and one breath hold scan. If the breath hold scan showed that 
the heart had been properly moved backwards, a new breath hold scan was obtained 2 days later, 
after the patient had practicing breath hold at home. The depth of inhalation was checked with the 
"breathing stick". This breathing stick was a ruler that was placed vertically on the skin of the epigastric 
area (just outside the irradiated area) at a marked point. The depth of the breath hold could be 
determined by reading this ruler. During treatment, the radiation technician could check visually, and 
the patient could 
feel, whether the tip of the stick made contact at the marked dot on the skin, ensuring a correct breath 
hold. Subsequently, this entire process was simplified to only the 2 CT scans on day 1, the trained scan 
was not necessary. Also, the breath hold appeared to be very reproducibly without using the breathing 
stick; the use of the breathing stick could therefore be omitted. In order to be able to simplify this 
technique step by step in a controlled way, we investigated the reproducibility in each step. We have 
analysed both the regular set-up photos and the results of epidosimetry. In epidosimetry, the dose is 
measured after the patient and compared with the expected dose, based on the initial treatment 
planning. In case of incorrect reproducibility, i.e. different position of the patient or deviant breath 
hold, you would measure an incorrect dose behind the patient. The results showed that, although 
there was quite some variation, both the geographical set-up and the measured dose in patients with 
vmDIBH did not differ significantly from patients who were irradiated during free breathing. 
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Follow up  
Patients are often treated by several medical specialists (surgeon, oncologist, radiation oncologist). It 
is impossible and undesirable, to visit the outpatient clinic of each doctor for several years, both 
because of the expanding outpatient clinic as of the time it will cost the patient. However, it is 
important for the doctor to obtain information concerning the late side effects or complications 
(toxicity), both to learn about the effects of their treatment, but also because of a social demand to 
make treatment effects transparent. In addition, the patient should be offered additional care if she 
or he suffers from late side effects. To investigate whether we would receive adequate information 
from patients by asking them to complete questionnaires about the toxicity, we established the 
outpatient clinic for late effects in breast cancer (OCLO) (chapter 5). We asked patients who were 
irradiated for breast cancer 10 years ago to complete a comprehensive questionnaire about side 
effects and the quality of life. They were also asked to visit the outpatient clinic once in order to 
compare their answers with the doctors' findings. 
Half of the patients (n = 341) were willing to fill in the questionnaires, 249 patients were willing to visit 
the outpatient clinic. We found that, at a group level, patients scored their toxicity a little higher than 
the doctor at the outpatient clinic reported. Consequently, we concluded that by using questionnaires 
to determine toxicity of the treatment, toxicity will certainly not be underestimated. It also turned out 
that the questionnaires can be used for identifying patients who need additional attention because of 
severe complaints; they can be asked to visit the outpatient clinic to look for solutions. We have 
therefore concluded that it is possible to rely on questionnaires the recording of late side-effects. 
 
Discussion and future perspectives 
In chapter 6 the results are discussed and some important (future) projects are mentioned. 
The ultimate goal is to use the results of the Young Boost Trial to make a prediction model for cosmetic 
outcome that can be used in the medical office. The patient and doctor can decide together on the 
intensity of the radiation (for example, whether or not to boost), whereby the patient can be well 
informed about the benefits (less chance of disease recurrence) and disadvantages (risk of side effects, 
for example worse cosmetic outcome). 
An important relatively new development is the oncoplastic surgery. An increasing number of patients 
is undergoing oncoplastic surgery. In oncoplastic surgery, the lumpectomy cavity is closed and the 
contour of the breast is restored by translation and / or rotation the remaining breast tissue. 
Obviously, the aim of oncoplastic surgery is a better cosmetic result. However, it could be that after 
oncoplastic surgery (more wounds in the breast as a result of displacement, perhaps more seroma), 
more fibrosis occurs as a result of the radiation therapy. Unfortunately, no long term cosmetic results 
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of oncoplastic surgery are available. To obtain more information about late side effects, it is important 
to record them in a structured way. 
Although we know more and more about risk factors concerning late side effects, there are still many 
uncertainties. Consequently, no consensus exists regarding optimal radiation treatment planning. For 
instance, is it more important to spare the heart as much as possible, resulting in underdosage at the 
medial side of the breast, or, in the case of a boost, a larger area in the breast receiving a higher dose, 
resulting in a worse cosmetic outcome? In the Netherlands, a project has been started to harmonize 
plan evaluation, with the aim of achieving national consensus. 
To spare the heart during the radiation treatment, various, more or less invasive methods are 
available, all based on the fact that a breath hold moves the heart out of the radiation field. In the 
Netherlands, proton therapy became just recently available. With proton therapy it is possible to 
irradiate the target volume very precise and save surrounding tissues (such as the heart). Patients with 
breast cancer are only eligible for this treatment in The Netherlands, when a clinically relevant 
reduction in the risk of late heart damage can be achieved with proton therapy. For now, this clinically 
relevant reduction of hearts injury is estimated based om a prognostic model. To demonstrate the 
benefit of proton therapy, it is important to record late toxicity. In the long term, for example, data 
can be used to demonstrate that proton therapy does indeed reduce the risk of heart damage.  
Therefore, there are several arguments for obtaining good follow-up data. In this thesis we made a 
proposal about how this could be possible (Chapter 5). 
 
Conclusion:  
We studied several aspects of late side effects. We found that the use of a photon boost instead of an 
electron boost, a high boost dose, cosmesis at baseline, adjuvant chemotherapy and boost volume 
have an adverse impact om cosmetic outcome. The next step will be to develop a nomogram to 
estimate cosmetic outcome, to use in shared decision making on radiation treatment.  
In addition, we found that our technique of vmDIBH is as reproducible as radiation therapy during free 
breathing, making it an easy and valuable tool to reduce irradiate heart volume and thereby late 
cardiac injury. Currently proton therapy is implemented in the Netherlands to further reduce cardiac 
injury in selected patients. 
Finally, we showed that scoring of late side-effects by patient questionnaires is a meaningful way to 
record late side-effects in a structured manner. It does not only enable identifying patients who need 
additional care, but it will also allow to analyse data at a group level, e.g. to analyse time-trends within 
the institute and differences between institutes. 
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Nederlandse samenvatting 
 
Borstkanker  
In hoofdstuk 1 is een inleiding gegeven op de behandeling van relatief vroeg stadium borstkanker en 
de bijwerkingen van bestraling, resulterend in de vraagstellingen in deze thesis. Borstkanker is de 
meest voorkomende vorm van kanker bij vrouwen en het risico om borstkanker te krijgen is 
toegenomen in de afgelopen decennia.  Inmiddels zal bij 1 op de 7 Nederlandse vrouwen ergens in 
haar leven de diagnose borstkanker gesteld worden. Tegelijkertijd is de behandeling van borstkanker 
sterk verbeterd, bijna 80% van alle vrouwen met de diagnose borstkanker leeft minimaal 10 jaar. Er is 
dus een toenemende groep vrouwen die borstkanker overleven en daarna lang(er) doorleven. Gezien 
de goede prognose van (met name vroeg ontdekte) borstkanker, is er steeds meer aandacht gekomen 
voor de late bijwerkingen van de behandeling van borstkanker. De focus is verlegd van verbeteren van 
de overleving naar verbeteren van de kwaliteit van leven, zonder dat de overleving daarbij slechter 
wordt.  
Naast operatieve behandeling en systemische behandeling (hormoontherapie en/of chemotherapie) 
worden veel patiënten met borstkanker ook bestraald. De borstsparende behandeling bestaat uit een 
operatie waarbij de tumor wordt verwijderd (lumpectomie), gevolgd door bestraling van de borst. 
Eventueel kan er nog chemotherapie of hormoontherapie toegevoegd worden. De aanvullende 
bestraling zorgt ervoor dat de kans op terugkeer van de ziekte in de borst met 60-70% verlaagd wordt. 
Indien geïndiceerd kan nog een extra dosis op het oorspronkelijke tumorgebied gegeven worden (de 
boost), dit zal het risico op terugkeer van de ziekte nog eens met een factor 2 verkleinen. Door bij een 
borstsparende behandeling een operatie te combineren met bestraling, is deze behandeling minstens 
net zo veilig als de borstamputaties die decennia geleden standaard verricht werden, echter met als 
voordeel dat vrouwen hun borst kunnen behouden.   
 
Bijwerkingen 
Helaas heeft iedere antikankerbehandeling ook bijwerkingen. In geval van bestraling worden ook 
gezonde cellen beschadigd door de bestraling. Bij de behandeling van borstkanker volgt de bestraling 
na de operatie. Er zijn dan in principe geen zichtbare kankercellen meer, de bestraling is een 
preventieve behandeling om eventuele niet zichtbare kankercellen uit te schakelen en daardoor te 
voorkomen dat de ziekte in een later stadium weer terug kan komen. Omdat we niet goed weten waar 
de niet zichtbare kankercel zich bevindt, bestralen we de hele borst (of een deel) al dan niet aangevuld 
met een boost op de plaats waar de tumor oorspronkelijk gezeten heeft en al dan niet aangevuld met 
de regio waar de okselklieren zich bevinden.  Eventuele late bijwerkingen die door de bestraling 
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zouden kunnen ontstaan, zijn een verminderde schouderfunctie, vochtophoping in de armen 
(lymfoedeem, in geval van bestraling van de okselklieren) en fibrose (verlittekening / verharding) van 
de borst. De kans op fibrose en de ernst van deze fibrose is groter bij een hogere bestralingsdosis. 
Omdat de borstbestraling met schampende velden toegediend wordt, is er ook klein risico op schade 
aan de longen en in geval van linkszijdige borstkanker, aan het hart. 
 
Het centrale thema van dit proefschrift was om inzicht te krijgen in verschillende aspecten van enkele 
late bijwerkingen: 
- Om cosmetische uitkomst te voorspellen, niet alleen om aanwijzingen te hebben over hoe de 
cosmetische uitkomst te verbeteren, maar ook om te gebruiken bij gedeelde besluitvorming 
bij de keuze voor een bestralingsbehandeling. Voor dit doel hebben we de gegevens van de 
Young Boost Trial (YBT) gebruikt. In deze studie werd het effect van een hogere boostdosis op 
het risico op een lokaal recidief en het cosmetische resultaat onderzocht bij patiënten ≤ 50 
jaar oud. We hebben de cosmetische uitkomst van de Young Boost Trial geanalyseerd. 
- Om late bijwerkingen (hartschade) te voorkomen door te onderzoeken of onze techniek 
(Voluntary moderately Deep Inspiration Breath Hold (vmDIBH)) van breath hold (bestralen 
met ingehouden adem) daadwerkelijk reproduceerbaar is. 
- Om alle late bijwerkingen op een gestructureerde manier te registreren: 
 om patiënten te identificeren die extra zorg nodig hebben 
 om de ontwikkeling van prognostische modellen mogelijk te maken 
 om uitkomstgegevens te kunnen vergelijken met andere radiotherapiecentra of met 
historische controles 
 
De drie doelstellingen van dit proefschrift waren daarmee:  
1. Bepalen welke factoren van invloed zijn op:  
a) Door de patiënte gerapporteerde cosmetiek  
b) Fibrose (gescoord door de arts) 
c) Cosmetiek (op basis van een softwareprogramma (BCCT.core))  
 
Om deze factoren te kunnen bepalen, hebben we geanalyseerd welke factoren geassocieerd zijn 
met een slechtere cosmetiek in de YBT. Daarnaast hebben we ook beschreven hoe vaak er matig 
tot ernstige fibrose werd gevonden en hebben we gekeken wat de risicofactoren waren voor 
matig tot ernstige fibrose (Hoofdstuk 2 & 3).   
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2. Onderzoeken en ontwikkelen van een gemakkelijke en reproduceerbare breath hold methode 
(bestralen met ingehouden adem) om zo de dosis in het hart zo laag mogelijk te krijgen (Voluntary 
moderately Deep Inspiration Breath Hold, vmDIBH). 
In hoofdstuk 4 beschrijven we hoe we deze vmDIBH stap voor stap hebben geïntroduceerd in ons 
instituut.  
 
3. Onderzoeken of vragenlijsten verstuurd aan patiënten betrouwbare informatie opleveren over 
late bijwerkingen (Hoofdstuk 5). 
 
Cosmetiek en fibrose 
De EORTC ‘‘boost versus no boost” studie had eerder al laten zien dat het risico op een lokaal recidief 
(het plaatselijk terugkeren van ziekte in de borst) verder verlaagd kan worden door het toevoegen van 
een boost aan de bestraling van de gehele borst, vergeleken met bestraling van de gehele borst alleen. 
In deze studie bleek echter dat het risico op terugkeer van de ziekte in de borst, ondanks het 
toevoegen van de boost, bij de jongere vrouwen nog steeds meer dan ruim 13% na 10 jaar was. Omdat 
dit als een te hoog risico werd beschouwd, werd in 2003 een nieuwe studie opgezet, de zogenaamde 
Young Boost Trial (YBT). In deze studie werden vrouwen van 50 jaar oud of jonger, met vroege, 
beperkte borstkanker geïncludeerd die een borstsparende operatie hadden ondergaan. Vervolgens 
werd er voor de bestralingsbehandeling geloot tussen een standaard boost dosis en een extra hoge 
boost dosis, in aanvulling op de standaard bestraling op de gehele borst. De resultaten wat betreft de 
invloed op de boost dosis op het risico van een lokaal recidief zijn nog niet gepubliceerd, maar de 
recidiefkans voor de totale studiepopulatie is veel lager dan tevoren was ingeschat (ongeveer 2.2% na 
8 jaar).  
In hoofdstuk 2 en 3 van dit proefschrift hebben we gegevens van de YBT gebruikt om de cosmetische 
uitkomst tot 4 jaar na de bestraling te analyseren. Cosmetiek is ontzettend moeilijk om te scoren, 
omdat het een hele subjectieve maat is. Wie bepaalt immers wat ‘mooi’ is? Om cosmetiek toch zo 
objectief mogelijk te kunnen scoren hebben we gebruik gemaakt van het BCCT.core programma. Dit 
is een softwareprogramma dat aan de hand van digitale foto’s van de borsten een score geeft. Foto’s 
worden beoordeeld op symmetrie (op basis van 7 symmetrie kenmerken) tussen beide borsten, de 
kleur van de huid en de zichtbaarheid van het litteken. BCCT.core geeft dan een score betreffende de 
cosmetiek: slecht, matig, goed of uitstekend.  
Hoewel een objectieve maat voor cosmetiek natuurlijk heel belangrijk is, vooral in studieverband of 
om verandering in de loop van de tijd goed te kunnen vervolgen, is de tevredenheid van de patiënte 
betreffende haar eigen borst ook van wezenlijk belang. In hoofdstuk 2 hebben we onderzocht welke 
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symmetrie kenmerken voor patiënten het belangrijkst zijn om tevreden te zijn met het uiterlijk van de 
borst. Uit onze analyse bleek dat de afstand tussen de tepel en de inframammair plooi (de onderrand 
van de borst), de lengte van de borstcontour en de mate van fibrose het meest bepalend te zijn voor 
patiënttevredenheid.  
In hoofdstuk 3 hebben we onderzocht welke behandeling-gerelateerde factoren invloed hebben op 
de cosmetiek, gemeten met de objectieve BCCT.core. Het bleek dat een hogere boost dosis in 
vergelijking met de standaard boost dosis, een fotonen boost in plaats van een elektronen boost, een 
al minder fraaie cosmetiek vóór start van de bestralingsbehandeling, een groter volume van de borst 
wat de boost dosis krijgt en het ondergaan van aanvullende chemotherapie, risicofactoren zijn om een 
minder fraaie borst te ontwikkelen in de follow up.  
 
Voorkómen van hartschade  
Bij bestraling van de borst of borstwand wordt over het algemeen het grootste deel van de dosis 
gegeven middels schampvelden. Bij linkszijdige borstkanker is het dan mogelijk dat het hart voor een 
deel in het bestralingsveld ligt. Het is bekend dat dosis in het hart kan leiden tot schade aan het hart, 
waarbij geldt dat hoe meer dosis in het hart, hoe groter de kans op hartklachten op termijn. Het is dus 
van belang om de dosis in het hart zo laag mogelijk te houden.  
Er zijn meerdere ademhalingstechnieken beschreven om het hart te sparen. Al deze technieken 
hebben als gemeenschappelijke deler dat bij een diepe inademing het hart verplaatst in de borstkas 
en weg beweegt van de borstwand. Een simpele en goedkope methode is op basis van een 
zogenaamde vrijwillige inademing. Echter, bij deze methode is het moeilijk om de inademing goed te 
controleren en daarom wordt getwijfeld aan de reproduceerbaarheid van deze methode.  
In hoofdstuk 4 beschrijven we stap voor stap hoe we deze voluntary moderate deep inspiration breath 
hold (vmDIBH) in Maastro hebben geïmplementeerd, en hoe we de techniek gedurende het 
implementatieproces vereenvoudigd hebben. Aanvankelijk kregen patiënten 3 CT-scans in 2 dagen, 
waarbij op dag 1 een CT-scan werd gemaakt in zowel vrije ademhaling als een scan met ingehouden 
adem. Indien op de CT-scan te zien was dat het hart op de scan met ingehouden adem goed naar 
achteren verplaatst was, werd 2 dagen later een nieuwe scan met ingehouden adem gemaakt, nadat 
patiënte thuis wat ademoefeningen had gedaan. De diepte van inademing werd gecontroleerd met 
het ‘ademstokje’. Dit ademstokje was een meetlat, die verticaal op de huid van de maagregio (net 
buiten het bestraalde gebied) geplaatst werd op een gemarkeerd punt. Door deze meetlat af te lezen, 
kon bepaald worden hoe diep de patiënte had ingeademd. Bij iedere bestraling kon dan gecontroleerd 
worden of patiënte even diep in had geademd. Vervolgens is dit hele proces vereenvoudigd naar 
alleen de 2 CT-scans op dag 1, een geoefende scan bleek niet nodig. Ook bleken patiënten heel 
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reproduceerbaar in te ademen zonder gebruik van het ademstokje; het gebruik van het ademstokje 
kon dus afgeschaft worden. Om deze techniek stap voor stap gecontroleerd te kunnen 
vereenvoudigen, hebben we in iedere stap de reproduceerbaarheid onderzocht.  Hiervoor hebben we 
zowel de reguliere set-up foto’s als resultaten van de epidosimetrie geanalyseerd. Bij epidosimetrie 
wordt de dosis achter de patiënte gemeten en vergeleken met wat we verwachtten te meten op basis 
van de initiële dosisberekeningen. Als de reproduceerbaarheid niet goed zou zijn en een patiënte 
telkens anders zou liggen en anders zou inademen zou je een andere dosis meten achter de patiënte. 
De resultaten lieten zien dat, ondanks dat er best wat variatie was, zowel de geografische set-up als 
de gemeten dosis bij patiënten met vmDIBH niet significant verschilden van patiënten die met de 
standaard vrije ademhaling bestraald werden. 
 
Follow up  
Patiënten worden vaak behandeld door meerdere specialisten (chirurg, oncoloog, radiotherapeut). 
Het is ondoenlijk en onwenselijk om bij alle artsen meerdere jaren op controle te blijven komen, zowel 
vanwege het uitpuilende spreekuur van de arts als vanwege de tijdinvestering die dat van de patiënte 
vraagt. Het is echter belangrijk voor de specialist om toch informatie te krijgen over de late 
bijwerkingen of complicaties (toxiciteit) die een patiënte ondervindt, zowel om te leren over de 
effecten van je behandeling, als ook omdat er een maatschappelijke vraag is om de behandeleffecten 
transparant te maken. Bovendien moet de patiënt extra zorg worden geboden als zij of hij last heeft 
van late bijwerkingen. Om te onderzoeken of we, door patiënten vragenlijsten in te laten vullen over 
de toxiciteit die ze ervaren, adequate informatie zouden krijgen, hebben we de polikliniek voor late 
effecten bij het mammacarcinoom (borstkanker) (PLEM) opgericht (hoofdstuk 5). We hebben 
patiënten die 10 jaar eerder bestraald waren voor borstkanker gevraagd om een uitgebreide 
vragenlijst in te vullen over bijwerkingen die zij ervaren en de kwaliteit van leven. Ook werd hen 
gevraagd om eenmalig op de polikliniek te komen zodat we de rapportage van de artsen konden 
vergelijken met die van patiënten.  
De helft van de patiënten (n=341) die we aangeschreven hebben, was bereid de vragenlijsten in te 
vullen, 249 patiënten waren bereid om ook op de polikliniek te komen. Het bleek dat op groepsniveau 
patiënten hun bijwerkingen iets ernstiger scoorden dan de arts op de poli dat deed. Door de 
vragenlijsten te gebruiken om de toxiciteit van de behandeling te bepalen, zal de toxiciteit dus zeker 
niet onderschat worden. Ook bleek dat we goed uit de vragenlijsten konden halen welke patiënten 
dermate ernstige bijwerkingen hadden, dat ze echt een keer op de polikliniek gezien moesten worden, 
om samen met hen te zoeken naar eventuele andere oorzaken van de klachten, en naar oplossingen 
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te zoeken. Wij hebben derhalve geconcludeerd dat het mogelijk is om op vragenlijsten te vertrouwen 
om de toxiciteit inzichtelijk te maken. 
 
Discussie en toekomstperspectieven 
In hoofdstuk 6 worden de resultaten bediscussieerd en in een breder kader geplaatst.  
Een belangrijk toekomstig doel is om met behulp van de resultaten van de Young Boost Trial een 
voorspellingsmodel betreffende de te verwachten cosmetiek te maken, dat gebruikt kan worden in 
de spreekkamer. De patiënte en de arts kunnen dan samen beslissen over de intensiteit van de 
bestraling (bijvoorbeeld wel of geen boost) waarbij de patiënte goed geïnformeerd kan worden over 
de voordelen (minder kans op terugkeer ziekte) en de nadelen (meer kans op bijwerkingen, zoals 
slechtere cosmetiek).  Een belangrijke relatief nieuwe ontwikkeling is daarbij de oncoplastische 
chirurgie. Patiënten worden steeds vaker oncoplastisch geopereerd. Bij oncoplastische chirurgie 
wordt de lumpectomieholte gesloten en wordt de contour van de borst hersteld door het resterende 
borstweefsel te verplaatsen en/of te draaien. Het doel van deze operatie is uiteraard een fraaier 
cosmetisch resultaat. Het zou echter kunnen dat door de oncoplastische chirurgie (meer wonden in 
de borst als gevolg van verplaatsing, wellicht meer seroom) er juist meer fibrose als gevolg van de 
bestraling optreedt. Helaas zijn er nog weinig data over de resultaten van deze operatie op de langere 
termijn.  Om meer informatie te verkrijgen over de late bijwerkingen, is het belangrijk om deze op een 
gestructureerde manier vast te leggen.  
Hoewel we steeds meer weten van risicofactoren betreffende late bijwerkingen, bestaan er ook nog 
veel onduidelijkheden. Als gevolg hiervan is er bijvoorbeeld nog geen consensus over het optimale 
bestralingsplan. Is het bijvoorbeeld belangrijker om het hart zo maximaal mogelijk te sparen, met als 
gevolg een onderdosering aan de binnenzijde van de borst, of, in geval van een boost, een groter 
gebied in de borst die een hogere dosis krijgt met als gevolg een minder fraaie cosmetiek? Inmiddels 
is er in Nederland een project gestart ten behoeve van harmonisatie van planevaluatie, met als doel 
landelijke consensus te bereiken.   
Om het hart te sparen tijdens de bestralingsbehandeling, hebben we laten zien dat de bestraling 
tijdens vrijwillige “breath hold” even goed reproduceerbaar is als bestraling in vrije ademhaling, zodat 
het een eenvoudige methode is om de kans op hartschade te verkleinen (hoofdstuk 4). Sinds kort 
hebben we in Nederland een drietal protonencentra. Met protonentherapie is het mogelijk heel 
nauwkeurig het doelgebied te bestralen en omgevende weefsels (zoals het hart) te sparen. Patiënten 
met borstkanker komen vooralsnog alleen in aanmerking voor deze behandeling als er met 
protonentherapie een klinisch relevante verlaging van het risico op late hartschade kan worden 
bereikt. Dit wordt nu ingeschat aan de hand van een model. Om de winst van de protonentherapie 
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aan te tonen, is het scoren van late toxiciteit belangrijk. Zo kan op de lange termijn middels data 
aangetoond worden dat protonentherapie inderdaad leidt tot een verlaging van het risico op 
hartschade.  
Er zijn dus meerdere argumenten om goede follow up data te verkrijgen. In dit proefschrift hebben 
we een voorstel gedaan over hoe dit mogelijk zou zijn (hoofdstuk 5).  
 
Conclusie:  
Concluderend hebben we verschillende aspecten van late bijwerkingen bestudeerd. Uit onze analyse 
bleek dat een hogere boost dosis in vergelijking met de standaard boost dosis, een fotonen boost in 
plaats van een elektronen boost, een al minder fraaie cosmetiek vóór start van de 
bestralingsbehandeling, een groter volume van de borst wat de boost dosis krijgt en het ondergaan 
van aanvullende chemotherapie, risicofactoren zijn om een minder fraaie borst te ontwikkelen. De 
volgende stap is het ontwikkelen van een nomogram om de cosmetische uitkomst te schatten, die 
gebruikt kan worden bij gedeelde besluitvorming over bestraling. 
Bovendien hebben we geconstateerd dat onze techniek van vmDIBH net zo reproduceerbaar is als 
bestralingstherapie tijdens vrije ademhaling, waardoor het een eenvoudig en waardevol hulpmiddel 
is om het bestraalde hartvolume en daardoor late hartschade te verminderen. Momenteel wordt 
protonentherapie in Nederland geïmplementeerd om hartschade bij geselecteerde patiënten verder 
te verminderen. 
Ten slotte hebben we aangetoond dat het scoren van late bijwerkingen door middel van patiënten 
vragenlijsten een zinvolle manier is om late bijwerkingen op een gestructureerde manier vast te 
leggen. Hiermee kunnen niet alleen patiënten worden geïdentificeerd die extra zorg nodig hebben, 
maar kunnen ook gegevens op groepsniveau worden geanalyseerd, b.v. tijd-trends binnen één 
instituut of verschillen tussen instituten. 
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Valorisation 
 
Relevance 
Breast cancer is the most common cancer in women1. In the last decades, the incidence of breast 
cancer has risen. In the Netherlands, over 17.000 women were diagnosed with breast cancer in 20192. 
At the same time, the treatment of breast cancer patients has improved substantially1,3, leading to a 
growing number of breast cancer survivors. Especially in the patient population with a good 
oncological prognosis, preventing late side effects becomes increasingly important.   
In this thesis we mainly focussed on three late side effects, namely cosmetic outcome, as we believe 
cosmetic outcome is related to quality of life, quality of life in a broader sense and preventing radiation 
induced heart damage.  
We analysed data of the Young Boost Trial regarding cosmetic outcome at 4 years of follow up. We 
investigated which symmetry features are most important for patients to be satisfied with the 
appearance of her breast after breast conserving therapy. These findings might be relevant for 
surgeons, when they need to decide about surgery techniques. Further, we were able to define some 
radiation related factors and adjuvant chemotherapy as risk factors for worse cosmetic outcome5. 
Having knowledge about the Dose Volume Histogram parameters which are important for 
deterioration of cosmetic outcome, can be helpful for the radiation oncologist when reviewing the 
treatment plan. In literature many other risk factors for cosmetic outcome are known. Although there 
is still a lack in knowledge concerning the order of importance of the different risk factors and with 
that how to deal with them, we feel that these results can be helpful when informing patients about 
the risks and benefits of the radiation treatment.  
We reported on the step-by-step implementation of a voluntary moderate deep inspiration breath 
hold technique6, a simple and inexpensive method to spare the heart in case of left sided breast 
cancer. It is known that dose to the heart can lead to heart damage, whereby the higher the dose in 
the heart, the higher the risk of heart disease during follow up. Therefore, it is important to keep the 
dose in the heart as low as possible. We showed a reproducible and affordable breath hold manoeuvre 
to reduce the dose to the heart. This paper can be helpful for radiation departments all over the world 
looking for a method to keep the dose in the heart as low as reasonable possible (ALARA). 
At last, we investigated whether patient reported outcome measures (PROMs) are sufficiently reliable 
to record late outcome7. We concluded that it is possible to rely on questionnaires for recording late 
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side-effects. These findings are very relevant for both breast cancer patients in the follow up as well 
as for breast cancer patients prior to the start of radiation therapy. By using PROMs, the patient can 
be saved a visit to the hospital during follow up. During consultation before start radiation therapy, 
patients can be informed regarding potential late side effects based upon the PROM data collected by 
the treating radiation therapy department. At last, we found that, although patients scored their 
toxicity a little higher than reported by the doctor at the outpatient clinic, questionnaires can be used 
to determine toxicity of treatment at a group level en therefore PROMs can be used for measuring 
quality of care.  
 
Target groups 
Breast cancer patients to be treated with curative intent, are the most important target group of this 
thesis. They may benefit directly or indirectly from the results obtained in this current thesis. For 
example, women with early breast cancer, treated with breast conserving therapy, can be better 
informed about the risk of deteriorated cosmetic outcome, if more is known about the risk factors 
predicting poor cosmetic outcome.  These data, in addition to data collected by PROMs, can be used 
in the shared decision making conservation with the patient. In addition, by worldwide implementing 
the relatively simple technique of voluntary moderately deep inspiration breath hold, much less 
women will experience radiation-induced cardiac injury. 
Furthermore, clinicians in the field of breast cancer and radiotherapy are likely to be interested in the 
results of our study. As a result of increasing attention of the government, health insurance companies 
and patient organizations for more transparency regarding quality indicators, it is important for all 
care providers to measure the quality of care. Using PROMs is a reliable method to record late effects 
of a treatment.  
 
Innovation 
Each of the studies in the current thesis has an innovative aspect. The Young Boost Trial is the only 
study with using a boost dose as high as 26 Gy. Further, the paper regarding the implementation of 
the voluntary moderate deep inspiration breath hold was the first article reporting on both set-up and 
in vivo dosimetric data obtained during breath hold, which is another form of innovation. At last, the 
development and design of the outpatient clinic for late outcome with the specific goal to investigate 
whether a visit to the hospital can be replaced by questionnaires to determine toxicity of the 
treatment can also be considered as innovative.  
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Planning & Realisation 
The analysis of the cosmetic outcome in the Young Boost Trial have provided clues regarding the risk 
of a deteriorated cosmetic outcome.  As described in the general discussion, the next step is to develop 
a nomogram to estimate cosmetic outcome. The results of PROMs will also allow development of 
prognostic models for other side effects that are considered to be relevant by patients. To find out 
exactly which late side effects patients consider to be relevant, a continuation of the BRASA study (a 
study with the aim to implement a decision aid for breast cancer and DCIS patients to decide on their 
radiation treatment) is currently under development. A workshop will be organized in which patients 
are asked patients for their opinion concerning relevant late side effects on which they might base 
their choice of treatment. In addition, patients are asked how this can best be visualized in the decision 
aid. In the future, these individualised predictions can then be used in shared decision making on 
radiation treatment.  
In the Netherlands, proton therapy has become available for almost two years. Patients with breast 
cancer are only eligible for this treatment in The Netherlands, when a clinically relevant reduction in 
the risk of late heart damage can be achieved with proton therapy. For now, this clinically relevant 
reduction of heart injury is estimated based om a prognostic model. To prove the benefit of proton 
therapy, it is important to record late toxicity. In the long term, for example, data can be used to 
demonstrate that proton therapy does indeed reduce the risk of heart damage. Another application 
of the use of questionnaires / PROMS is, as mentioned above, to get insight in the toxicity of your own 
patient population. Radiotherapy departments will be able to compare (benchmark) their score on 
late toxicity with other radiotherapy departments. Departments that perform below average will be 
motivated to improve and the best performing departments can be asked to share their best practice 
with the other departments to allow them to improve.  
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Dankwoord 
Het zit erop! Mijn promotietraject is afgerond en ‘het boekje’ is klaar. Dit proefschrift was echter nooit 
tot stand gekomen zonder de bijdrage van anderen. Met het gevaar iemand te vergeten, excuus alvast 
daarvoor, zou ik toch graag een aantal mensen persoonlijk bedanken. 
Om te beginnen alle patiënten die hebben deelgenomen aan de Young Boost Trial en alle patiënten 
die de moeite hebben willen nemen belangeloos naar de late effecten poli voor borstkanker te komen 
en/of de vragenlijst in te vullen. Deze poli dag was de dag dat ik mijn witte jas weer aan kon trekken 
en zo kon ik tijdens de bureau-jaren toch het contact met de kliniek onderhouden.  
Uiteraard mijn oprechte dank voor mijn promotoren prof. dr. L.J. Boersma en prof. dr. D. de Ruysscher 
en mijn copromotor dr. J.G.M. van Loon. Beste Liesbeth, toen ik bij je aanklopte of je “iets” had voor 
de verplichte onderzoeksstage, had je een prachtig project klaarliggen, namelijk de cosmetiekanalyse 
van de Young Boost Trial. Omdat we de Young Boost trial niet wilden uitmelken, hebben we het 
onderwerp van deze thesis verbreed en ook de implementatie van de vmDIBH in het boekje 
opgenomen en samen de late effecten poli voor borstkanker opgezet. Dank voor je enthousiasme, het 
delen van je kennis, voor je begeleiding en vooral ook voor je geduld. Het heeft even geduurd, maar 
ik denk dat we nu toch een prachtig resultaat hebben afgeleverd. Je hebt al vele promovendi begeleidt 
als copromotor, maar ik ben de eerste promovendi waar jij de promotor van bent en daar ben ik 
ontzettend trots op! Beste Dirk, juist doordat borstkanker niet jouw aandachtsgebied is, kon je soms 
de vinger precies op de juiste plek leggen, waardoor bepaalde alinea’s toch wat genuanceerd moesten 
worden of beter uitgelegd. Dank voor de immer kritische blik.  Beste Judith, hoe bijzonder eigenlijk 
dat wij zijn begonnen als AIOS-collega’s en dat je later mijn copromotor werd. Dank voor altijd de 
laatste blik. Vaak als ik dacht klaar te zijn, het document rondgestuurd werd met naamgeving .def,  
kwam jij nog met een paar laatste verbetertips   
Ook zou ik graag de leden van beoordelingscommissie, professor René van der Hulst, dr. Astrid 
Scholten, dr. Desirée van den Bongard, professor Ignace de Hingh en dr. Stéphanie Peeters willen 
bedanken voor het (snelle!) beoordelen van mijn proefschrift en de bereidheid plaats te nemen in de 
beoordelingscommissie.  
Ook alle co-auteurs van de artikelen verdienen een woord van dank, waarbij ik Erik van Werkhoven 
uit het AvL in het bijzonder wil noemen. Erik, dank voor het iedere keer weer analyseren wat wij 
vroegen en dank voor de herhaalde uitleg van het proportional odds principe.  
John Paulissen, dank voor je hulp in de late effectenpoli. Zonder jou had ik er 2x zo lang over gedaan 
om alle patiënten te zien.  
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Bianca Hanbeukers, dank voor je hulp bij het evalueren van de cosmetiek. Duizenden foto’s moesten 
door BCCT.core geanalyseerd worden. Heel fijn dat ik ze niet allemaal alleen hoefden te doen! 
Alle datamanagers, doktersassistenten en secretaresses die ervoor gezorgd hebben dat de late 
effectenpoli zo goed liep, dank! Ook de datamanagers van het Antonie van Leeuwenhoek ziekenhuis, 
dank voor alle queries die jullie zowel nationaal als internationaal uitgezet hebben zodat de database 
uiteindelijk toch compleet was.  
Ruud Houben, dank voor je statistische hulp. Ondanks echt goede cijfers voor Wiskunde A en het 
statistiek tentamen, had ik de papers niet zonder jouw hulp kunnen schrijven.  
Wie zeker niet vergeten mag worden is Mariëlle Vincken. Mariëlle, ik heb het eerder gezegd en ik 
herhaal het nu weer: je bent een engel! Zo ontzettend fijn dat je de secretariële ondersteuning 
rondom de goedkeuring van mijn promotie, alle papieren rompslomp en het plannen van de datum 
op je hebt willen nemen. Een en ander werd je niet gemakkelijk gemaakt door de universiteit hack en 
de coronacrisis, maar je hebt het toch maar mooi geregeld voor me, ontzettend bedankt! 
Antoinette Mulder, dank voor het ontwerpen van de kaft van mijn boekje. Ik had iets in m’n hoofd en 
je wist nog net iets mooiers te tekenen dan ik eigenlijk in mijn hoofd had.  
Inmiddels werk ik alweer ruim 1 jaar met heel veel plezier in het ZRTI als radiotherapeut-oncoloog. 
Bedankt lieve collega’s voor de fijne werkomgeving, de belangstelling en de steun. Zo fijn als er de dag 
nadat je verlof hebt opgenomen om eens 2 dagen achter elkaar ongestoord te kunnen werken, er een 
blokje ‘administratie proefschrift’ in je agenda staat  
Ook iedereen bedankt die mij als radiotherapeut-oncoloog hebben gevormd. Om te beginnen alle 
oud-AIOS waar ik zo’n gezellige opleidingstijd mee heb gehad. Daarnaast alle (oud)radiotherapeut-
oncologen van Maastro en het Catharina Ziekenhuis en in het bijzonder al mijn opleiders en 
plaatsvervangend opleiders Philippe Lambin, Jos Jager, Rinus Wanders, Angela van Baardwijk, Tom 
Budiharto en Hetty van den Berg bedankt voor het opleiden van mij. Zonder jullie was ik nooit de arts 
geworden die ik nu ben. Ook alle oud-collega’s uit het Leids Universitair Medisch Centrum en het 
Reinier de Graaf Gasthuis bedankt voor de fijne tijd in de randstad. De transformatie van AIOS naar 
medisch specialist heb ik in een veilige omgeving mogen maken.  
Ook dank voor Maaike en Hanneke dat ze mijn paranimfen willen zijn. Lieve Maaike, jij was al AIOS 
toen ik begon. Gelukkig heb je mij mijn goedbedoelde, maar minder geslaagde opmerking heel snel 
vergeven en zaten wel al heel snel meermaals per week samen op de spinningfiets en later op de 
mountainbike. Jij hebt het Zeeuwse verruild voor Zuid-Limburg, ik ben nu juist in Zeeland beland. 
Grappig dat onze laatste stelling dezelfde is! Lieve Hanneke, ergens halverwege mijn opleiding kwam 
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bij de AIOS-groep binnenstormen als vrolijke enthousiasteling. Samen hebben we een ontzettend 
gezellige tijd in Eindhoven gehad en hebben we zelfs “samen” Maastrichts Mooiste gelopen. Fijn dat 
je weer terug aan de slag gaat als radiotherapeut-oncoloog. Zonde van zo’n lieve en prettige dokter 
als de witte jas aan de wilgen wordt gehangen!   
Mijn vrienden en familie wil bedanken voor al het geduld wat ze met me hebben gehad. Regelmatig 
heb ik het af laten weten bij een verjaardag omdat ik echt achter de laptop moest kruipen. 
Tegelijkertijd wil ik jullie ook bedanken voor alle leuke dingen waar ik wel bij kon zijn. Aangezien de 
totstandkoming van dit proefschrift meerdere jaren heeft geduurd, kon de boog echt niet altijd 
gespannen staan. Mar & Wout, Steef & Sander, Heico & Eef en Ed & Triz, op het vriendenweekend van 
2 jaar geleden kon ik echt weer even teren! Frank & Pascalle, altijd gezellige logeerpartijen na een high 
tea en de kermis.  Bea en Sara, wat bof ik dat ik jullie zo snel heb leren kennen hier in Middelburg. 
Dankzij jullie voel ik me al helemaal thuis en ik hoop dat er nog vele gezellige BBQ / spelletjes / concert 
avondjes mogen volgen! 
Lieve papa en mama, bedankt voor alles! Jullie hebben mij altijd gesteund, niet alleen tijdens mijn 
promotietraject, maar door alle jaren heen. Zowel tijdens de opleiding, als alle verhuizingen, altijd 
hebben jullie mij geholpen waar mogelijk was. Altijd hebben jullie oprechte interesse getoond in mijn 
werkzaamheden en jullie hebben me altijd laten weten dat jullie trots op mij zijn. Ik ben blij dat ik jullie 
als ouders heb! 
Annemarie en Jeroen, mijn grote zus en “kleine” broertje. Als pubers boterde het niet altijd even goed, 
gelukkig zijn we inmiddels volwassen en zijn we opgedroogd als een leuk gezin met altijd gezellige 
familievakanties. Ook al wonen we niet naast de deur, hopelijk komt er nu toch wat meer tijd om weer 
eens gezellig samen af te spreken, nu ik niet altijd ‘nog iets moet doen’.  
Tot slot mijn lieve Martijn, dank dat je voor mij de keuze om te gaan promoveren zoveel gemakkelijker 
hebt gemaakt door naar Maastricht te verhuizen. Dank voor je technische hulp, door jouw 
programmeer-tool spraken de data veel meer tot mijn verbeelding. Dank voor je geduld en begrip als 
ik weer aan het werk moest. Dank voor je opbeurende woorden en knuffels als ik er even doorheen 
zat. Maar vooral wil ik je bedanken voor wie je bent, en dat je mij laat zijn wie ik ben.  
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Curriculum vitae 
Patricia Brouwers werd geboren op 23 mei 1980 in de Moer (gemeente Loon op Zand), waar zij ook 
opgroeide. Na het VWO aan het Teresialyceum te Tilburg startte zij in 1998 met de opleiding 
geneeskunde aan de Erasmus Universiteit Rotterdam. Na het artsexamen in februari 2005 was zij 
werkzaam als arts-assistent-niet-in-opleiding bij de afdeling chirurgie in het Ruwaard van Putten 
ziekenhuis in Spijkenisse, als arts-assistent-niet-in-opleiding op de intensive care van het Elisabeth 
Ziekenhuis Tilburg, als arts-assistent-niet-in-opleiding spoedeisende hulp van het Elisabeth 
Ziekenhuis/Tweesteden Ziekenhuis Tilburg en als arts-assistent-niet-in-opleiding bij de afdeling 
radiotherapie in het Instituut Verbeeten. Bij deze laatste vond zij bevestiging betreffende de 
specialisatie richting, waarna zij in september 2009 startte met de opleiding radiotherapie bij 
MAASTRO clinic met als opleiders dr. A van Baardwijk en drs. R. Wanders (aanvankelijk dr. J. Jager en 
prof. Dr. P. Lambin). Tijdens de perifere stage in het Catharina Ziekenhuis te Eindhoven in het laatste 
jaar waren de opleiders dr. T. Budiharto en drs. H. van de Berg.  
De opleiding werd van 2013 t/m 2015 onderbroken voor haar promotieonderzoek, onder begeleiding 
van prof. dr. L.J. Boersma, dr. J.G.M. van Loon en prof. dr. D. de Ruysscher. Haar promotieonderzoek 
betrof de late effecten van bestraling bij patiënten met borstkanker, waarbij risicofactoren 
betreffende cosmetiek werden geanalyseerd op basis van data uit de Young Boost Trial. Ook werd een 
simpele breath hold beschreven om het hart tijdens de bestraling zoveel mogelijk uit het 
bestralingsveld te bewegen en werd onderzocht of late effecten scoren in de follow up ook mogelijk 
is middels vragenlijsten.  
De opleiding werd voltooid in september 2017, waarna zij startte als radiotherapeut-oncoloog in het 
LUMC in Leiden. Sinds mei 2019 is zij werkzaam als radiotherapeut-oncoloog bij het Zuidwest 
Radiotherapeutisch Instituut in Vlissingen. Haar huidige aandachtsgebieden zijn mammatumoren, 
gastro-intestinale tumoren en urologische tumoren. 
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